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ABSTRACT
Alhamdan, Nasser. M.S., Microbiology and Immunology Graduate Program. Wright
State University, 2017. Genomic vs. Non-genomic Role of the AhR in Human
Immunoglobulin Expression.

The immunoglobulin heavy chain gene (Igh) in various animal models is regulated
by numerous regulatory elements including the 3’Igh regulatory region (3’IghRR). Several
transcription factors are involved in modulating the 3’IghRR including the aryl
hydrocarbon receptor (AhR). The AhR is a ligand-activated transcription factor that
mediates the transcription of genes involved in the metabolism of environmental toxicants
such as TCDD. TCDD binds AhR and regulates immunoglobulin (Ig) expression in B cells.
This modulation appears to be directly mediated by binding of the AhR to dioxin response
elements (DRE) within the 3’IghRR. In human B cells, IgG secretion inhibited by TCDD
and increased by chemical antagonist of the AhR (AhRA). AhR can interact with different
transcription factors like NFκB and AP-1, and modulate signaling pathways such as Src
and Akt pathways. the human CL-01 cells express a nonfunctional transactivation domain
(AhR TA) in one of its alleles. Therefore, we hypothesized that in human cells the AhR
regulates IGH expression by altering 3’IGHRR activation through both genomic and nongenomic mediated mechanisms. The current study focuses on determining the potential
non-genomic effects of the AhR on the activation of cytosolic signaling proteins such as
Src and Akt, and transcription factors like NFκB and AP-1. In addition, it evaluates the
genomic effects of the nonfunctional AhR TA on the 3’IGHRR reporter activity and
evaluates the role of AhR in the effect of the TCDD and AhRA on Ig expressing and
3’IGHRR activity. Our results showed that the AhR has non-genomic effects by activating
cytosolic signaling protein like Akt and increasing the Iγ3-3’IGHRR reporter activity in
iii

response to AhRA that could lead to an increase in IgG secretion. The nonfunctional AhR
TA decreased the AhR binding to DRE sites as demonstrated in a DRE reporter but it did
not affect 3’IGHRR activity in response to TCDD or AhRA. AhR knockdown by gene
editing demonstrated inhibition of IgG secretion and AhRA had no effect on Iγ3-3’IGHRR
activity, supporting the suggested a physiological non-genomic role of the AhR in the
expression of IgG. Determining the role of the 3’IGHRR and its potential difference in
sensitivity to the AhR could provide new insight into potential environmental triggers of
immune disorders and provide new targets for drug development.
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I.

INTRODUCTION
The immune system
The immune system is a host defense system that consists of a cooperative network
between cells, organs and tissues to protect the body. This network has mechanisms that
identify and neutralize different threats to the human body. Threats can be arise from
harmful alterations happening inside the body such as dysregulation of a normal cell into
a tumor cell or that may enter the body from the outside such as infectious bacteria or toxic
agents. The immune system has the ability to differentiate self-organisms and molecules
from nonself and contains two lines of defense against threats. The first line is the innate
immune system that include a group of well-maintained chemical, mechanical and
microbiological barriers that prevent pathogens from entering the body. In the event that
these barriers are penetrated, the nonspecific components of the innate immune system,
then the second line, which is the specific adaptive immune system, are activated (Parham,
2009).
Each defense system has special recognizing mechanisms that has advantages and
disadvantages. The mechanisms of innate immune system are ready for action. It has fast
response that just takes a few hours to distinguish pathogens. Some of the innate immunity
mechanisms are constantly work even if there is no pathogen, for example antimicrobial
proteins continuously secreted into gut. This system is non-specific because it responds the
same to a variety of antigens and it attacks all pathogens equally. The core components of
innate immunity include macrophages, neutrophils and natural killer cells. Once the
pathogen invades the body, the innate effector cells recognize pathogen-associated
1

molecular patterns (PAMPs) through pattern recognition receptors (PRR) expressed on the
surface of innate effector cells. Pathogen recognition induces innate effector cells to secrete
inflammatory mediators such as cytokines and chemokines. In contrast, the adaptive
immune system has slower reactions and it may takes days or even weeks to recognize
antigens and support an immune response, but antigens are selected by highly specificity.
The adaptive immunity generates an immune response by antibody-mediated immunity or
cell- mediated immunity as well as immunological memory, which gives the host longterm protection from reinfection by the same specific pathogen (Parham, 2009). Innate and
adaptive immunity cooperate by a lot of cross-reaction between the two mechanisms. For
example, some of the innate system cells are critical for activation of the adaptive system
cells and can in turn have their activity elevated and directed by activated cells from the
adaptive system (Doan, et.al, 2008).
The adaptive immune system has unique cells and molecules. It is the second level
of defense against potential threats to the body, following the barriers and the innate
immune system. It can eliminate specific antigens by either cell-mediated immunity or
antibody-mediated (humoral) immunity. Cell-mediated immunity is dominated by T cells
that bind to antigens presented on the cell surface via major histocompatibility complex
(MHC). T cells express CD4+ (T helper) that bind to antigens presented by MHC molecules
class II (MHC II). These molecules are exclusively expressed on antigen-presenting cells,
which include macrophages, dendritic cells, and B-cells. Binding of CD4+ T-helper cells
with (MHC II) molecules leads to proliferation and differentiation of the T-helper cells into
memory, effector or regulatory T helper cells. Moreover, T cells expressing CD8 (cytotoxic
T cells) bind to an antigen presented by MHC class I, which is expressed by nearly all
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nucleated cells of the body. Cytotoxic T-cells are specialized to recognize and fight cancer
cells and intracellular infection by destroying cells presenting foreign intracellular antigen
in their MHC I. On the other hand, antibody-mediated immunity is mediated by B cells
that differentiate into antibody-forming cells (plasma cells), which produce specific
antibodies against a particular epitope: the part of an antigen that is recognized by
antibodies (Parham, 2005).
B cells
B cells are the main effectors of the antibody-mediated response of adaptive
immunity. Like other cells, B cells are created in the bone marrow and then circulate as
immature or mature B cells through blood and lymph nodes to the secondary lymphoid
tissue like the spleen. B cells have transmembrane proteins called B-cell receptor (BCR)
located on the surface of B cells. Each BCR has only one isotype of a membrane-bound
immunoglobulin (Ig), and all isotypes on the same B cell have the same antigen-binding
site. Mature B cells that express IgM and IgD on their surface and have not been exposed
to antigens are called naïve. They circulate in the bloodstream and lymph as inactive B
cells, and once they recognize specific antigens, they become activated and differentiate
into antibody-secreting cells (plasma cells).
In order to activate B cells, a signal provided by antigen and interaction with helper
T cells stimulates B cells to proliferate and differentiate into plasma cells or long-lived
memory B cells. Plasma cells secrete a huge amount of antibodies, the soluble form of Ig,
in response to antigen and release them into the circulation. The amount of antibodies
production decrease as the stimulus of infection is removed by the elimination of the
pathogen from the body. The antibodies can be present in the circulation for several months
3

afterward. The IgM antibody isotype mediates the primary immune response when mature
B cells encounter antigen for the first time and differentiate to produce memory cells (longlived cells) and plasma cells. On the other hand, the secondary immune response mediated
when memory B cells are re-expose to the same antigen, is a faster immune response and
these cells produce a huge amount of specific and high-affinity antibodies of different
isotypes such as IgG.
Immunoglobulins
Ig proteins are the critical ingredients at every stage of the humoral acquired
immune response. Antibodies are the Ig that are secreted from B cells and travel through
the circulation to bind to the specific antigens that triggered their production (Parslow et.al,
2001). Ig contains four polypeptides chains: two identical light chains (IgL) and two
identical heavy chains (IgH) linked by disulfide bonds to form a monomeric subunit (Fig.
1). The antigen-binding site (epitope-binding site) at the tip of the arm is formed by a
single heavy chain and a single light chain. A single antibody subunit is bivalent due to the
two arms, which have identical antigen-binding sites. Each chain has a C-terminal end with
a constant amino acid sequence (constant region) and an N-terminal end with a variable
amino acid sequence (variable region), which is responsible for the huge diversity of the
antigen binding site. Heavy chains contain one variable (VH) domain and three or four
constant (CH) domains (Fig. 1). There are five isotypes of Ig (IgM, IgD, IgG, IgE and IgA),
each isotype is encoded by a specific constant region within the Ig heavy chain gene: Cμ,
Cδ, Cγ, Cε, and Cα are encoded for isotypes IgM, IgD, IgG, IgE, and IgA respectively. In
human, there are four IgG subclasses IgG1, IgG2, IgG3 and IgG4 encoded by Cγ1, Cγ2,
Cγ3 and Cγ4 heavy chain genes, respectively and two IgA subclasses IgA1 and IgA2
4

encoded by Cα1 and Cα2 heavy chain genes, respectively. Normally, humans produce two
types of light chain, kappa (κ) or lambda (λ). Light chains contain one variable (VL) domain
and one constant (CL) domain. In an individual B cell, each Ig monomer contains two
identical kappa (κ) or two identical lambda (λ) but never both (Doan, et.al, 2008).
The IgM isotype is the first Ig formed and is found as a monomer on the B-cell
surface. Once B cells differentiate into plasma cell, IgM is secreted as a pentamer resulting
in a total of 10 antigen-binding sites. IgM is the primary antibody secreted in a primary
response. As the response progresses somatic hypermutation and class switch
recombination are engaged, which will result in a change in the antibody isotype and in the
immune response according to the type of encountered antigen.
The IgD isotype has a monomeric structure and is mostly displayed on the B-cell
surface. It works as a co-receptor along with IgM and it can activate basophils and mast
cells to coordinate an immune response that eliminates bacteria (Parham, 2005).
The IgG isotypes (IgG1-4) are secreted as monomers and they are the most
abundant antibody in the serum. IgG is produced by B cells in a huge amount during a
secondary immune response and it is the only Ig isotype that can cross the placental barrier
to give immunity to the fetus. It can activate complement, and neutralize microorganism
and viruses (Doan, et.al, 2008).
The IgA isotypes (IgA1-2) are the main antibody found in body secretions. IgA can
be secreted as a monomer as found in the serum or as a dimer as found in secretions,
including milk, saliva, sweat, tears, and intestinal secretions. IgA provides protection
against microbes in body secretions.
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The IgE isotype is secreted as a monomer and binds to mast cells, eosinophils, and
basophiles in the absence of antigen. When antigen binds to IgE on eosinophil, a strong
physical reaction and inflammatory reaction is triggered to kill parasites, while IgE on mast
cells and basophils triggers the release of histamine leading to immediate hypersensitivity
responses (Doan, et.al, 2008).
Somatic recombination or VDJ recombination happen during early B lymphocyte
development in the bone marrow to form the antigen-binding sites. It is assembly of the
variable (V), diversity (D) and joining (J) gene segments that gives rise to the variable
region exons of the antigen receptor. The V and J gene segments encode the light chain
variable region (VL), while the heavy chain variable region (VH) also has the D segments
along with V and J. VDJ recombination needs recombination activating genes 1 and 2
(RAG-1 and RAG-2) to complete this process. In the heavy chain (VH), random D and J
gene segments recombine together and the intervening DNA sequences between them are
deleted. Eventually, the D-J recombination is joined to a V gene segment to get a
rearranged VDJ gene segment. In the light chain variable region (V L), only one
recombination V to J takes place. V(D)J recombination helps to produce high diversity of
antigen binding sites. When mature B cells interact with antigen, they undergo two more
forms of genetic change within the Ig genes: somatic hypermutation (SHM) and isotype
class switch recombination (CSR). In somatic hypermutation, point mutations are induced
within the DNA sequences of the heavy and light chain variable regions with the aim of
increasing Ig affinity for a particular antigen. Class switch recombination refers to isotype
switching from IgM to IgG, IgE or IgA isotypes. CSR occurs only in the heavy chain
constant region (CH) by joining the rearranged variable region exon to a different
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downstream constant region (i.e. Cγ1-4, Cε, or Cα1-2), and delete the intervening germline
DNA. These events enable a rearranged V-region to be used with other heavy chain Cregions in order to express different antibody isotypes with the same antigen specificity
(Parham, 2005).

7

Figure 1. Structure of Immunoglobulin. Four polypeptide chains consisting of two
identical light chains and two identical heavy chains linked by disulfide bonds form the Ig
monomeric unit. Each chain has a variable region that forms the antigen binding sites, and
each heavy chain contains a constant region that determines the function of Ig.
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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
Dioxins refer to a group of toxic chemicals that consist of halogenated aromatic
hydrocarbons (HAH). They have similarities in structure, properties, and mechanisms.
HAH includes polychlorinated biphenyls (PCB), polychlorinated dibenzofurans (PCDF),
and polychlorinated dibenzodioxins (PCDD). Dioxins have a long half-life and
hydrophobic properties make them resistance to metabolism. This tend to bio-accumulate
of dioxins in adipose tissues, especially with long-term exposure, and persist as
environmental contaminants (Mandal 2005; Van den Berg et al., 1998).
The most studied PCDD is the potent and highly toxic dioxin 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD). It is a planner molecule (C12H4Cl4O2) and insoluble
in water (Fig. 2). In addition, it has no odor or color at room temperature and it is not
intentionally produced by industry except in a limited quantity for research purposes.
TCDD is produced from many industrial processes that have incomplete combustion of
organic materials in presence of chlorine such as plastic production, herbicides and
pesticides. Also it is produced from improper disposal of medical waste, metal smelting,
diesel trucks, burning treated wood and forest fires (Malisch & Kotz, 2014; Strucinski et
al., 2011). Biological effects of TCDD are dependent upon many factors including
exposure duration and dose as well as species. In fact, exposure to TCDD could be through
ingestion of contaminated food or water, inhalation of contaminated dust or cigarette
smoke, and direct contact with incorporated soil or surfaces (Mandal, 2005).
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Figure 2. Chemical structure of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD).

During the Vietnam War (1961-1971), TCDD was discovered to be a contaminant
in the herbicide Agent Orange when American military forces sprayed it on foliage to
expose Vietnamese soldiers (Karch, et al., 2004). Additionally, in Seveso, Italy (1976),
thousands of inhabitants were exposed to TCDD after an accidental explosion of a pressure
tank containing substances contaminated with TCDD leading to the highest residential
exposure to TCDD (Mandal 2005). Another incident happened in Vienna 1997 when two
women were poisoned at their workplace with the highest measured dose of TCDD in
human (144 ng/g of fat) (Geusau et al., 2001). The second highest exposure happened in
Ukraine during the 2004 election campaign when Viktor Yushchenko was poisoned with
TCDD (108 ng/g of fat) after a failed assassination attempt (Sorg et al. 2009). Humans
seem to be less sensitive to toxic effects by TCDD than many laboratory animals (Poland
& Knutson, 1982). In animal studies, exposure to TCDD caused immune dysfunction,
endocrine disruption, teratogenesis, hepatic damage and tumorigenesis (Mandal 2005).
10

TCDD is not acutely life-threatening in humans but has been shown to induce death in
sensitive animal species. For example, the lethal dose 50% (LD50) for TCDD varies from
1 μg/kg for guinea pig, the most sensitive animal species, to >5000 μg/kg for hamster, the
most resistant (Poland & Knutson, 1982). The main effects of TCDD on human in shortterm include blurred vision, nausea and development of severe chloracne. Whereas the
long-term effects include vascular ocular changes, signs of neural system damage and
immunological effects include effects on B cell lead to low level of immunoglobulin IgG
in the circulation (Silbergeld & Gasiewicz, 1989; Dertinger et al., 2001; Marinkovic et al.,
2010). Additionally, TCDD has been classified as a human carcinogen because it promotes
cancer development (IARC, 1997). The mechanism of TCDD toxicity in human is not clear
yet, but the biological effects are thought to be mediated by the aryl hydrocarbon receptor
(AhR) signaling pathway.

11

The Aryl Hydrocarbon Receptor (AhR) Signaling Pathway
The aryl hydrocarbon receptor (AhR) is a cytosolic receptor protein. It is a ligandactivated transcription factor that is encoded by the Ahr gene and consists of 848 amino
acids. The structure of AhR comprises of a basic-helix-loop-helix domain followed by PerARNT-Sim protein domain (PAS). Therefore, it is part of the bHLH/PAS family of
transcription factors (Gu et al., 2000). In mouse, the high concentrations of AhR have been
found in most tissues especially thymus, liver and kidney, while in humans, it can be found
in the placenta, lung, and liver, and low concentrations in brain, muscle and kidney
(Carlstedt-Duke, 1979; Carver et al., 1994a; Dolwick et al., 1993; Yamamoto et al., 2004).
The AhR is activated through binding to a variety of endogenous or exogenous ligands. A
number of endogenous compounds such as indoles, 7-ketocholesterol, bilirubin and
tetrapyroles have been identified as AhR ligands (Denison & Nagy, 2003). The majority
of high-affinity AhR ligands are exogenous ligands like polycyclic aromatic hydrocarbons
(PAHs) and halogenated aromatic hydrocarbons (HAHs). The ligand with the highest AhR
binding affinity is 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Fig. 2). It is part of the
HAH family and the prototypical ligand used in AhR studies (Abel and HaarmannSteeman, 2010).
In the absent of a ligand, AhR is an inactive protein located in the cytosol and bound
to protective proteins to stabilize the whole complex. This complex consists of a dimer of
heat-shock proteins (Hsp90) that protects from cell temperature elevation; co-chaperone
p23, which prevents non-specific binding to ARNT; and XAP2, which binds to AhR and
Hsp90 (Whitlock, 1999). Once ligand (e.g. TCDD) binds to the AhR in the cytoplasm, the
AhR protein goes through a conformational change leading to its dissociation from the
12

complex of protective cytosolic proteins (Fig. 3). Then the TCDD-AhR complex
translocates from the cytoplasm into the nucleus where it binds to the aryl hydrocarbon
receptor nuclear translocator (ARNT) to form a heterodimer. The TCDD-AhR-ARNT
heterodimer complex binds to specific DNA sequences (5’-TNGCGTG-3’) called dioxin
responsive elements (DRE). Since DREs are located within the promoter or enhancer
regions of target genes, the heterodimer complex causes upregulation or downregulation
of gene expression (Abel & Haarmann-Stemmann, 2010) (Fig. 3). If the AhR ligand, which
activates AhR signaling, is no longer present, the activation of the AhR can be controlled
by either of two regulatory pathways; negative feedback inhibition mediated by the AhR
transcriptional repressor (AHRR) or cytosolic export of the AhR and degradation by
ubiquitination and proteasome pathways (Abel & Haarmann-Stemmann, 2010).

13

Figure 3. Aryl hydrocarbon receptor signaling pathway. TCDD binds to the AhR and
cytoplasmic proteins dissociate. TCDD-AhR translocates to the nucleus and binds ARNT.
The complex of TCDD-AhR-ARNT binds to DRE sequences and modulates transcription.
CYP1A1 is a sensitive indicator of AhR activation.
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The AhR has an important role in the regulation of xenobiotic metabolizing
enzymes and drug metabolizing enzymes such as cytochrome P450A1 (CYP1A1) (Fig. 3).
CYP1A1 is highly induced by TCDD, and it is one of the most characterized genes
regulated by the AhR. It has been used as a biomarker for AhR activation (Hansen et al.,
2014; Whitlock, 1999). In addition to drug metabolism, the AhR signaling pathway is
involved in crosstalk pathways with steroid receptors of androgen, estrogen and
progesterone hormones by co-regulating gene transcription and expression (Ohtake et al.,
2008). Moreover, the AhR plays an important role in proliferation, differentiation,
apoptosis and survival of cells. Also, it has effects in the immune system, it mediates
immunological responses by inhibiting inflammation through induction of interleukin-22
(IL-22) and down-regulation of Th17 and CD4+ T cell response (Monteleone et al., 2011;
Wei et al., 2014), and the AhR has main role in inhibition of Ig production through
suppression of B-cell proliferation and differentiation (Sulentic & Kaminski, 2011).
Mouse AhR studies show that the AhR is highly responsive to TCDD and the
mouse AhR has ten-fold higher affinity compared to the human AhR (Denison et al., 1986).
In addition, the human and mouse AhR gene have single nucleotide polymorphisms (SNPs)
in different locations and they only share about 58% amino acid sequence identity in the
C-terminal of the gene, which includes the transactivation domain (Flaveny et al. 2008).
The SNPs in exon 10 of the human AhR have been reported in association with decreased
CYP1A1 induction by AhR in response to TCDD (Wong, et al., 2001). The lower affinity
of the human AhR and the exon 10 SNPs may explain why animal models are more
sensitive to TCDD than human. Interestingly, the exon 10 SNPs did not affect the ligand
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binding affinity, also the SNPs located in the ligand-binding domain did not affect the
ligand-induced CYP1A1 expression (Harper et al., 2002).
The Aryl Hydrocarbon Receptor Antagonist (AhRA)
In animal models, the AhR plays an important role in mediating toxicity and
inducing activity of the TCDD; therefore inactivation of the AhR signaling pathway would
be estimated to offer protection from TCDD toxicity. High affinity ligands for the AhR
include toxic compounds such as halogenated aromatic hydrocarbons HAHs, polycyclic
aromatic hydrocarbons PAHs and PAH-like compounds (Denison et al., 1998). Other
natural and endogenous AhR ligands have been identified but they have different chemical
structures and characteristics from HAH and PAH AhR ligands, which suggests that the
ligand-binding pocket of the AhR is very promiscuous (Denison et al., 1998). Since
structurally diverse ligands can bind to different amino acids within the ligand-binding
pocket of the AhR, it could be possible to determine an antagonist that could affect one or
a group of ligands over another (Zhao et al. 2010). Some of the AhR antagonists lack of
specificity due to two reasons; they have binding affinity to the estrogen receptor that
enhance the estrogen-related effects or they are partial agonists such as flavones that at
high doses act as AhR agonists (Zhang et al., 2003; Amakura et al. 2002). The CH223191
compound has been identified as a pure AhR antagonist, which competes and inhibits
binding of TCDD to the AhR, and prevents the AhR from translocating to the nucleus and
binding the DNA (Fig. 4) (Kim et al. 2006). It is a selective AhR antagonist for HAH
compounds while no antagonism effect on AhR activated by different concentration of
PAH or non-PAH AhR agonists (Zhao et al. 2010). In addition, it does not show AhR
agonist-like activity at high doses or any binding affinity to the estrogen receptor, therefore
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CH223191 (AhRA) is the best candidate compound to elucidate the role of the AhR when
it is activated by TCDD (Zhao et al. 2010). This compound has been tested in our lab with
the mouse B-cell line (CH12.LX) and it inhibits the AhR signaling pathway and decreases
the expression of CYP1A1 in response to TCDD (Wourms & Sulentic, 2015). In another
study on the CL-01 human B-cell line, the AhRA and TCDD demonstrated inconstant
effects on IgM secretion but they antagonized each other’s effect on IgG secretion.
Surprisingly, activated CL-01 cells by the AhRA induced IgG secretion by two-fold (Burra,
2015 data not published).
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Figure 4. AhR antagonist (AhRA) inhibits translocation of AhR into the nucleus.
AhRA competes and blocks TCDD binding to the AhR as well as TCDD-mediated nuclear
translocation and DNA binding activity of the AhR.
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The Immunological effects of TCDD
The immune system is an early and sensitive target to TCDD-induced toxicity. A
wide range of TCDD concentrations can cause significant immunological dysfunction
including suppression of both innate and adaptive immunity and inhibition of cell-mediated
and humoral immunity (Mandal, 2005; Abel & Haarmann-Stemmann, 2010). In animal
studies, acute or chronic exposure to TCDD causes thymic atrophy, endocrine disruption,
hepatic damage and immunological effects include immune-cell dysfunction and
suppression of immune responses that lead to susceptibility to infectious diseases
(Kerkvliet, 2002; Mandal, 2005; Safe, 1998). TCDD improved the induction of Treg cells,
which suppressed T-cell proliferation (Quintana et al. 2008), and TCDD inhibited Ig
production through suppression of B-cell differentiation (Sulentic & Kaminski, 2011). As
mentioned the effects of TCDD on humans are less sensitive than animals (Denison et al.,
1986). In human, several epidemiological studies found that an association between people
exposed to TCDD and non-Hodgkin’s lymphoma or multiple myeloma (Becher et al.,
1996; Hooiveld et al., 1998). Among people living in highly TCDD contaminated area,
there was 2.3 times greater incidence of non-Hodgkin’s lymphoma than people living in
low TCDD contamination (Floret et al., 2003). Another study found that prenatal exposure
to TCDD affects humoral immune status of their children after birth through demonstrated
of reduced vaccine titers and increased incidence of otitis and chicken pox (ten Tusscher
et al., 2003). Moreover, exposure to TCDD for a long time mediates B-cell immunotoxicity
such as markedly decreased the IgG levels in circulation (Baccarelli et al., 2002). TCDD
also increased the production of only IgE isotypes from B cells isolated from atopic patients
(Kimata, 2003).
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TCDD-Induced B-cell Dysfunction
B cells are an essential component of the humoral immune response and are a
sensitive direct target of TCDD. In mouse models, TCDD affects B-cell maturation and
gene regulation that lead to suppression of immunoglobulin production (Lu et al. 2010;
Sulentic and Kaminski 2011). TCDD inhibits B-cells differentiation into antibody-forming
cells mediated by the AhR (Wourms & Sulentic, 2015; Vorderstrasse et al., 2001). TCDD
inhibits B-cell differentiation induced with T-helper function (T-dependent) by activating
B-cell with sheep red blood cells or without T-helper function (T-independent) using
lipopolysaccharide (LPS) for activating B-cell (Holsapple et al., 1986). In a mouse B-cell
line (CH12.LX) stimulated with LPS, TCDD in a concentration-dependent manner (0.0330nM TCDD) decreased IgM secretion, whereas it did not affect IgM secretion in an AhRdeficient B-cell line (BCL-1) stimulated with LPS, suggesting that AhR plays an important
role in inhibition of IgM secretion by TCDD (Sulentic et al., 1998). Moreover, in an IgA
secreting B-cell line that has the AhR knocked down by shRNA or the AhR inhibited by
an AhR antagonist prevented TCDD-induced inhibition of IgA secretion (Wourms &
Sulentic, 2015). Another study with AhR-/- mice showed normal immune function and Ig
production after treatment with TCDD (Vorderstrasse et al., 2001). These studies support
an important role of the AhR in TCDD-induced inhibition of Ig and B-cell differentiation
and inactivation of the AhR has no effect in normal immune function (Wourms & Sulentic,
2015; Vorderstrasse et al., 2001).
Human B-cells appear to have a variable response to TCDD. In human primary Bcells, TCDD suppressed IgM in nine donors while having no effect in two donors and
increased IgM in one donor (Lu et al., 2010). In addition, it suppressed the differentiation
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of human primary B cells by inhibiting the activation markers CD69, CD86 and CD80 (Lu
et al. 2011). In a study of people who live in TCDD-contaminated areas including residents
in Seveso, Italy and Korean veterans, decreased plasma IgG levels were reported
(Baccarelli et al., 2002 ; Kim et al., 2003). In another study on human B cells, TCDD had
variable effects on IgM secretion and µ IGH functional transcripts while IgG secretion and
γ1-4 germline/functional transcripts were inhibited (Burra 2015, unpublished data). Whereas
in tonsillar mature B cells, TCDD induced IgE production without affecting production of
other Ig isotypes (IgG, IgM or IgA) in patients with allergic rhinitis, atopic
eczema/dermatitis syndrome, or bronchial asthma with no effects on Ig isotypes in other
patients, suggesting that allergic diseases could be aggravated by TCDD (Kimata, 2003).
Additionally, the Ig heavy chain regulatory region (3’IghRR) mediates TCDD-induced
suppression of B-cell differentiation in mouse models but its role in humans is unknown
(Wourms & Sulentic, 2015; Fernando et al., 2012; Sulentic et al., 1998). Overall, the
mechanism of TCDD and AhR in mediating B-cell dysregulation by TCDD in mouse is
relatively well defined whereas the mechanism in humans is still unclear.
Immunoglobulin Heavy Chain (IgH) Locus
The human Ig heavy chain (IGH) gene is located on chromosome 14 and the mouse
Ig heavy chain (Igh) gene is located on chromosome 12. They encode the heavy chain of
antibodies during early B-cell development and differentiation by DNA remodeling events
such as VDJ recombination, class switch recombination (CSR), and somatic hypermutation
(SHM) (Pinaud et al. 2011). The rearranged Ig heavy chain (IGH) gene consists of variable
heavy chain promotor (VH), variable region (VDJ), the heavy chain intronic enhancer (Eµ),
the heavy chain constant region genes (CH), and the 3’ immunoglobulin heavy chain
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regulatory region (3’IgHRR) (Fig. 5) (Mills et al. 1997). The VH promoter initiates and
regulates the transcription of the IGH locus and gene expression, while the VDJ gene
encodes the antigen binding sites. The intronic enhancer (Eµ) is important for efficient VDJ
recombination and Cµ expression (Perlot et al. 2005). In Burkitt’s lymphoma, translocation
of the 3’IGHRR with the cellular oncogene MYC deregulates gene expression (Yan et al.,
2007). In addition, the chromosomal translocation between BCL-2 gene and 3’IGHRR in
follicular lymphomas deregulates gene expression and increases cell death resistance
(Heckman et al., 2003). Other studies showed that Igh transcription in a mutant myeloma
cell line was significantly inhibited after deletion in a sequence downstream of Cα leading
to the discovery of the 3’IghRR (Gregor & Morrison, 1986). The mouse and human heavy
chain locus are 90% homologous but there are some differences (Mills et al. 1997). The
human IGH has two groups of constant regions with two 3’IGHRRs each has three
enhancers (hs3, hs1.2, hs4) while the mouse Igh has one group of constant region with one
3’IghRR that has four enhancers (hs3a, hs1.2, hs3b, hs4) (Fig. 5). In human IGH, upstream
of each 3’IGHRR are constant region genes that encoding for specific heavy chain isotypes.
The first set of heavy chain constant region (CH) genes include Cμ, Cδ, Cγ3, Cγ1, Cψε and
Cα1, followed by the first regulatory region 3’IGHRR-1. The second set of constant region
genes located downstream of 3’IGHRR-1 that include Cγ2, Cγ4, Cε and Cα2, followed by
the second regulatory region 3’IGHRR-2 (Mills et al. 1997). The mouse Igh has one set of
CH genes that include Cμ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε and Cα followed by one regulatory
region 3’IghRR (Fig. 5) (Madisen and Groudine 1994).
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Figure 5. Human and mouse immunoglobulin heavy chain (Iɡh) gene locus. VH,
variable heavy chain promoter; Eμ, intronic enhancer; long rectangles, IgH constant region
genes; short rectangles, germline promoters; 3’IghRR, regulatory region; hs,
hypersensitivity site.
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The mouse 3’ Immunoglobulin Heavy Chain Regulatory Region (3’IghRR)
The mouse Igh locus has one 3’IghRR and this region is about a 40 kb DNA
segment. The main role of the 3’IghRR is to control and regulate the transcription of the
Igh gene and class switch recombination (CSR), but it does not appear to play a role in
VDJ recombination (Cogne et al., 1994; Ju, Chatterjee, & Birshtein, 2011). It has four
major DNAase I hypersensitive elements (hs3a, hs1.2, hs3b, and hs4), which are regions
of chromatin that are sensitive to cleavage by the DNase I enzyme (Fig. 5). The hs1.2
enhancer has transcriptional activity in a mature B cell and plasma cell, the hs3a and hs3b
enhancers have minor activity in B cells or plasma cells, while the hs4 has transcriptional
activity throughout B-cell development especially pre-B cell and plasma cells.
Replacement of mouse hs1.2 enhancer with neomycin resistance gene resulted in decreased
CSR into IgG2a, IgG2b, IgG3 and IgE (Cogne 1994). On the other hand, the four enhancers
display maximum activity at all stages of B-cell development when all four enhancers are
link together (Matthias and Baltimore, 1993; Madisen and Groudine, 1994; Chauveau et
al., 1998; Saleque et al., 1997). They have several binding sites for transcription factors
including DRE, NF-κB, Octamer (OCT), NF-αP, AP-1/Ets, and Pax5 that regulate
3’IghRR activity (Fig. 6). Therefore the mouse 3’IghRR could be a sensitive target of
several exogenous and endogenous toxic chemicals such as the AhR-ligand TCDD.
Past research shows that transcriptional activity of mouse 3’IghRR in CH12.LX
cells stimulated with LPS is inhibited by TCDD (Sulentic et al., 2004a). This effect matches
the suppression of Cµ gene expression and IgM secretion by TCDD (Sulentic et al., 2000).
The mouse 3'IghRR has a DRE motif in the most transcriptional active enhancers hs1.2
and hs4, and TCDD was shown to induce binding of AhR/ARNT to DRE sites within these
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enhancers (Salisbury & Sulentic, 2015; Sulentic et al., 2000). Suggesting that mouse
3’IghRR is a transcriptional target of the AhR signaling pathway, and because this region
is important for CSR and Igh transcription, it could mediate the TCDD-inhibitory effect on
the Ig expression (Sulentic et al., 2004a). However, 3’IghRR enhancers react differently
with TCDD when evaluated in isolation. When the CH12.LX cell line was transfected with
a plasmid reporter regulated by either the hs4 or the hs1.2 enhancer, the transcriptional
activity of the hs4 enhancer was increased, while the hs1.2 enhancer was suppressed by
TCDD (Sulentic et al., 2004b; Fernando et al., 2012). Moreover, the deletion of the hs4
enhancer does not affect class switch recombination (CSR) or Ig production in mouse cells
stimulated with LPS or cytokines (Vincent-Fabert et al., 2009). These outcomes are against
the effect of TCDD on the full length 3’IghRR suggesting that the hs4 enhancer has an
unrelated or different role with TCDD while inhibition of the hs1.2 enhancer by TCDD
may be responsible for the inhibitory effect on 3’IghRR transcriptional activity.
Interestingly, the mouse hs1.2 enhancer has two binding sites for paired box protein (Pax5)
but the human hs1.2 enhancer does not have any Pax5 binding sites (Fig. 6) (Schneider et
al., 2009). The Pax5 transcription factor plays a main role in early stages of B-cell
development and must be downregulated to allow for differentiation of B cells into plasma
cells (Cobaleda et al., 2007). Pax5 levels are decreased in LPS-stimulated mouse B-cell,
but TCDD co-treatment inhibits this down-regulation (Yoo et al., 2004; Schneider et al.,
2008). Deregulation of Pax5 expression after TCDD treatment implies that Pax5 plays a
role in TCDD-mediated inhibition of Ig expression and B-cell differentiation (Schneider et
al., 2009).
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The Human Immunoglobulin Heavy Chain Regulatory Region (3’IGHRR)
The human IGH locus has two regulatory regions: 3’IGHRR-1 located downstream
of Cα1 and the 3’IGHRR-2 located downstream of Cα2. Each regulatory region is
composed of three DNAase I hypersensitive elements (hs3, hs1.2 and hs4) (Fig. 5)
(Chauveau & Cogne, 1996; Mills et al., 1997). The duplication of the 3’IGHRR in the
human locus is thought to be functionally significant, but no studies have investigated the
specific roles of the two 3’IGHRRs in antibody expression. The three human enhancers,
hs3, hs1.2 and hs4, share 74%, 90% and 76% similarity, respectively to the mouse
enhancers. TCDD treatment was expected to result in reduced activity of the 3’IGHRR
since TCDD is known to act as an immunosuppressant in both mouse and human B cells.
In luciferase reporter studies, when the human 3’IGHRR plasmids with different promotors
(i.e. VH, Iγ3 and Iε) were transfected into B cells and treated with TCDD, they exhibited
highly variable and statistically insignificant change in activity (Alfaheeda 2016,
unpublished data). In addition, several lymphomas, which are B-cell malignancies, have
chromosomal translocation between oncogenes like C-MYC or BCL-2 and the heavy chain
regulatory region 3’IGHRR that lead to cancer such as Burkitt’s lymphoma or multiple
myeloma (Heckman et al., 2003).
Among the three human enhancers, the human hs1.2 enhancer is the most important
one and it plays a main function in the control of transcription (Guglielmi et al., 2004;
Cogne et al., 1994). Unlike the mouse hs1.2, the human hs1.2 enhancer actually decreases
activity in response to human B-cell stimulation and increases activity in response to
TCDD in both a mouse (CH12.LX) and human (IM-9) B-cell line, which is exactly the
opposite of the stimulatory effect of cellular activation on the mouse hs1.2 and inhibition
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by TCDD (Fernando et al., 2012). Additionally, the activity of the human hs4 enhancer
alone is slightly reduced by TCDD unlike the stimulatory effect of TCDD on mouse hs4
activation (Alfaheeda 2016, unpublished data). These conflicting results between hs1.2 and
hs4 enhancers could partially explain why 3’IGHRR plasmid did not respond to TCDD at
all. The AhR antagonist was used to confirm that TCDD-induced activation of human hs1.2
enhancer requires the AhR (Fernando et al. 2012). Other studies have shown that the AhR
can bind to other transcription factors like SP1, NF-κB and AP-1 (Suh et al., 2002; Tian et
al., 1999; Kobayashi et al., 1996) therefore, the AhR could be directly or indirectly
involved in the hs1.2 activation by TCDD.
The hs1.2 enhancer in mouse and human are almost the same and similar in about
90% of the DNA sequences, but there are many important differences between them that
could explain the different effects by TCDD (Mills et al., 1997). The human hs1.2 enhancer
has a polymorphic region consisting of a 55 bp repeated sequence called the invariant
sequence (IS), which can be repeated up to four times, and appears to alter transcriptional
activity (Fig. 6). This polymorphism does not occur in the mouse hs1.2 enhancer (Denizot
et al., 2001) so all studies involving the mouse Igh locus have missed any functional
significance of the human polymorphism. Moreover, the IS has binding sites for several
transcription factors including NF-κB, NF-1, AP-1 and the AhR (Fig. 6). Unlike the mouse
enhancers, the human enhancers have NF-1 binding sites but they do not have binding sites
for Pax5 transcription factor, which is a negative regulator of B-cell differentiation into
antibody-secreting cells (Fernando et al. 2012; Chen and Birshtein 1997; Denizot et al.
2001). The transcription factors binding sites are increased with each additional IS, which
is correlated with an increase in the basal transcriptional activity of the hs1.2 enhancer
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(Cogné et al., 1994). The NF-1 binding site could mediate the TCDD-induced activation
of human hs1.2 enhancer since the mutation of the NF-1 binding site has a lower sensitivity
to TCDD (Snyder 2016, unpublished data). In contrast, another study found that mutation
of the AP-1 and NF-κB site increased the human hs1.2 enhancer activity by TCDD
suggesting that these sites have repressor roles (Ochs 2012, unpublished data). The
polymorphic region in the human hs1.2 enhancer makes the human heavy chain locus more
complex than the mouse locus. This polymorphism has drawn particular interest, because
it has been associated with Burkitt’s lymphoma and a number of autoimmune disorders
such as celiac disease, psoriatic arthritis, IgA nephropathy, rheumatoid arthritis, systemic
sclerosis, and plaque psoriasis. The hs1.2 allele 2, which has two IS repeats, has been
correlated with enhanced prevalence or severity of the previous disorders (Tolusso et al.,
2009; Giambra et al., 2009; Cianci et al., 2008; Aupetit et al., 2000; Frezza et al., 2004).
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Figure 6. Differences between mouse and human hs1.2 enhancers. The hs1.2 enhancer
is densely packed with transcription factor binding sites. A 55 base pair invariant sequence
(IS) in human hs1.2 enhancer is polymorphic and can be repeated up to four times. AP-1
activator protein 1; Oct, octamer; Sp1, specificity protein 1; NF-κB, nuclear factor kappa
B cells; DRE, dioxin responsive element; NF-1, nuclear factor 1; Pax5, paired box 5.
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AhR interacts with cytosolic signaling proteins.
In the absent of a ligand, AhR is an inactive protein located in the cytosol and bound
to protective proteins complex. Once ligand binds to the AhR in the cytoplasm, the AhR
protein goes through a conformational change leading to its dissociation from the complex
of protective cytosolic proteins (Abel & Haarmann-Stemmann, 2010). An additional
mechanism for the AhR activity is through protein-protein interactions with regulatory
proteins such as Src protein kinase and NFκB after dissociation from the proteins complex
in the cytosol (Enan and Matsumura, 1996; Tian et al., 1999). Moreover, the AhR signaling
pathway has been shown to modulate a number of signaling pathways such as tyrosine
kinases associated with the epidermal growth factor receptor (EGFR) and Akt/PKB
(Marlowe & Puga, 2005). Therefore, the biological effects of the AhR could occur via at
least two general mechanisms: direct influence on gene transcription by binding to DRE
motifs and/or modulate signaling pathways by protein–protein interaction (Suh et al.,
2002).
Src family kinases are cytoplasmic proteins that are associated with the plasma
membrane via lipid anchors at their N termini. The Src tyrosine kinase is overexpressed
and activated in B-cell malignancies and dysregulation of Src activity is thought to be the
key contributor to oncogenesis (Ye et al., 2016). Src family kinases (Lyn, Fyn, Fgr, Blk)
play a role in initial phosphorylation of cytoplasmic immunoreceptor tyrosine-based
activation motif (ITAM) of the Igα and Igβ that activate Syk, which is the dominant
tyrosine kinase activity in B cells, leading to B-cell activation (Xu et al.,2012). Indeed, Src
deficient mice displayed a profound block in B-cell development (Stepanek et al., 2013).
Moreover, Park et al. (2007) indicated that TCDD-induced activation of Src kinase is
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mediated by the cross-talk between the ligand-activated AhR in the cytosol and the
cytosolic Src chaperone complex (Src-cdc37-Hsp90 complex). In another study, Src
protein kinase is associated specifically with the cytosolic AhR complex along with hsp90
and upon ligand binding to the AhR, Src is activated and released from the complex (Enan
& Matsumura, 1996).
Consistent with Src kinase, the phosphoinositide 3-kinase (PI3K)/protein kinase B
(Akt) pathway plays a crucial role in multiple cellular processes, including cell
proliferation, angiogenesis, metabolism, differentiation and survival. The members of the
PI3K/Akt pathway are dysregulated in a wide spectrum of human B-cell cancers. Akt
signaling triggers a cascade of responses, from cell growth and proliferation to survival
and motility, which drive tumor progression (Vivanco, & Sawyers, 2002). Phosphorylated
Akt activates the mTOR complex, causing increased mRNA translation, protein synthesis
and cellular proliferation (Agata et al., 2010). Akt/forkhead box O (FoxO) pathway is a
major pathway involved in B-cell differentiation and function. Activation of BCR by
antigen leads to the transformation phosphatidylinositol bisphosphate (PIP2) to
phosphatidylinositol triphosphate (PIP3) that phosphorylates Akt. The p-Akt enters the
nucleus to inactivate FOXO protein, which blocks cell cycle progression and promotes
stress resistance, that help in B-cell prolifration (Limon & Fruman, 2012). Basal expression
of p-Akt was observed in the CA46 Burkitt lymphoma cell line under untreated conditions
(Huang et al., 2012). Many studies have shown that AhR regulates Akt activation. Lack of
the AhR leads to impaired activation of Akt and enhanced sensitivity to apoptosis in a
hepatoma cell line (LA1) (Wu et al., 2007). Another study showed that the AhR signaling
pathway controls breast cancer cell proliferation and development through inhibition of the
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phosphatase and tensin homolog (PTEN) and activation of β-Catenin and Akt pathways
(Al-Dhfyan et al., 2017).
The nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) protein
is sequestered in the cytoplasm and their activity is regulated by binding of inhibitory κB
factors (IκB). Upon activation, NFκB dimers dissociate from IκB and translocate to the
nucleus then bind to the NFκB binding sites (κB site) in promoters and enhancers of NFκB
responsive genes, consequently activating their transcription (Doi et al., 1997). The
NFκB/Rel plays a main role in regulation of B-cell activation and diffrentiation
(Gerondakis & Siebenlist, 2009). RelA/p50 is the major NFκB in pre-B cells and plays an
important role in certain steps of B-cell development (Liou et al., 1994). RelA-deficient
mouse B cells have the ability to secrete all immunoglobulins except IgG1 and IgA were
reduced (Doi et al., 1997). The AhR and NFκB pathways interact by physical association
of Re1A and AhR, and this interaction is associated with modulation of gene expression
(Tian et al., 1999). The κB binding site is close proximity to the DRE binding site within
the hs1.2 enhancer while it overlaps the DRE site within the hs4 enhancer (Sulentic et al.,
2000). Binding of both the AhR and NFκB cooperatively influenced hs4 reporter activity
(Sulentic et al., 2004b). Moreover, another study suggested that interaction between the
AhR and NFκB proteins mediates the inhibitory effects of TCDD on 3’IghRR and Ig
expression (Salisbury & Sulentic, 2015).
AP-1 is another transcription factor binding site in the hs1.2 enhancer of the
3’IGHRR (Pinaud et al., 2011). B-cell signaling initiated at TLRs activates Jun N-terminal
kinase (JNK). JNK phosphorylates c-Jun and c-Fos, which are components of AP-1,
increasing the AP-1 transcription activity that lead to plasmacytic differentiation and Ig
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production (North et al., 2010). AP-1 forms a transcriptional complex with ETS in
activated B cells that bind to an ETS/AP-1 motif in the mouse 3’IghRR enhancers that
plays a main role in class switch recombination (Grant et al., 1995). It has a main role in
the regulation of B-cell activation and differentiation since the surface IgM cross-linking
or activation of CD40 induced the expression of AP-1 (Chan et al., 1993). In addition, AP1 is involved in Ig production by transactivation of the promoter for κ light chain (Schanke
et al., 1994). Another study showed that inhibition of AP-1 activity by TCDD is AhRdependent and partially contributes to TCDD-mediated suppression of IgM expression in
mouse B cells (Suh et al., 2002).
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Hypothesis and Objectives:
In a mouse B-cell line, TCDD suppresses B-cell differentiation and inhibits IgM
secretion (Sulentic & Kaminski, 2011). This suppression is mediated by the AhR pathway
(Wourms & Sulentic, 2015; Vorderstrasse et al., 2001) perhaps by the AhR binding DRE
sites within the hs1.2 enhancer of the mouse 3’IghRR (Sulentic et al., 2000; Salisbury &
Sulentic, 2015). Moreover, the AhRA (CH223191) inhibits the AhR signaling pathway and
decreases the inhibition of Ig production in response to TCDD (Wourms & Sulentic, 2015;
Salisbury & Sulentic, 2015). In a human B-cell line, IgG secretion is inhibited in response
to TCDD but antagonism of the AhR [CH223191 or 6,2’,4’,-trimethoxyflavone (TMF)]
increased IgG secretion about two-fold (Burra 2015; Panstingel 2017, unpublished data).
In addition, AhR knockdown by shRNA showed that IgG secretion was nearly eliminated
(Kashgari 2015, unpublished data). Other studies have shown that the AhR can interact
directly or indirectly with different transcription factors like SP1, NF-κB and AP-1
(Kobayashi et al., 1996; Suh et al., 2002; Tian et al., 1999). The AhR signaling pathway
has also been shown to modulate a number of signaling pathways such as Src and Akt/PKB
(Marlowe & Puga, 2005). These data suggested that the AhR antagonist could cause a
conformational change in the cytosolic AhR resulting in activation of other cytoplasmic
proteins that leads to an increase in IgG secretion. In addition, the human AhR has SNPs
that decrease CYP1A1 induction by TCDD (Flaveny et al. 2008; Wong, et al., 2001). In
CL-01 human B cells, AhR is heterozygous with a non-functional transactivation domain
in one of its alleles due to three SNPs in exon-10 (Kashgari 2015, unpublished data). These
SNPs could explain why TCDD has variable effects on human 3’IGHRR reporters in the
CL-01 cells (Alfaheeda 2016, unpublished data). Moreover, knockout of the AhR will help
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to elucidate the role of the AhR in Ig expression and 3’IGHRR activity in response to
TCDD or AhR antagonism. Therefore, we hypothesized that in human cells the AhR
regulates IGH expression by altering 3’IGHRR activation through both genomic and nongenomic mediated mechanisms. To test this hypothesis, three main experimental objectives
were developed utilizing the human CL-01 B-cell line. Objective one was to evaluate the
potential non-genomic effects of the AhR on the activation of cytosolic signaling proteins
(i.e. phosphorylation and activation of downstream transcription factors). Objective two
was to determine the role of the AhR transactivation domain in the regulation and activity
of the 3’IGHRR enhancers by using CL-01 cells expressing an AhR with a functional
transactivation domain. Objective three was to directly evaluate the role of the AhR in the
effects of the AhRA and TCDD on Ig expression and 3’IGHRR activity using CRISPR/Cas
9 gene editing to knockout the AhR. Significantly, the human 3’IGHRR has a
polymorphism in the hs1.2 enhancer that has been associated with Burkitt’s lymphoma and
a number of autoimmune disorders such as celiac disease, psoriatic arthritis, IgA
nephropathy, rheumatoid arthritis, systemic sclerosis, and plaque psoriasis. Consequently,
determining the role of the 3’IGHRR and its potential sensitivity to the AhR could provide
a greater understanding of IGH regulation in general and new insight into potential
environmental triggers of immune disorders, perhaps providing new targets for drug
development.
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II MATRIALS AND METHODS
Chemical and Reagents
TCDD with 99.1% purity was purchased from AccuStandard, Inc and was
dissolved in 100% DMSO. Dimethyl sulfoxide (DMSO) was purchased from SigmaAldrich (St. Louis, MO). R848, a TLR 7/8 ligand, was dissolved in 100% DMSO and was
purchased from Enzo Life Sciences. The AhR antagonist (CH223191) was purchased from
Calbiochem (Carlsbad, CA) and was dissolved in 100% DMSO. Human interleukin 4 (hIL4) was purchased from Cell Signaling and dissolved in 1x phosphate buffer saline (PBS)
with 10% bovine calf serum (BCS). Human Mega CD40 ligand (CD40L) was purchased
from Enzo Life Sciences (San Diego, CA) and was reconstituted in 100 μl sterile H2O and
further dilution in fresh media with 10% BCS.
Cell Line Models
The Novus CL-01 human cell line was isolated from a Burkitt’s lymphoma patient.
It is a human monoclonal B-cell line that expresses surface IgM and IgD. It was purchased
from Novus Biologicals (Littleton, CO). Cells were cultured at 37°C in a 5% CO 2
atmosphere and grown in RPMI-1640 (Mediatech, Herndon, VA) enhanced with 2 mM Lglutamine, 10% BCS (Hyclone, Logan, UT), 13.5 mM HEPES, 0.1 mM nonessential amino
acids, 1.0 mM sodium pyruvate, 100 units/ml penicillin, 100 μg/ml streptomycin, 50 μM
β-mercaptoethanol and 23.8 mM sodium bicarbonate. The medium was changed every 23 days by simply removing some supernatant and adding some fresh medium. CL-01 cell
line is EBV transformed and the cells can activate each other easily by cell-cell contact.
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The cells were kept in density within the range between 0.1-0.2 x 106 cell/ml. they would
be hyper-activated if too crowded, and die if too diluted. The cells were discarded after 45 generations or after one month of thawing the cells unless requiring linger culture to do
growing up a clone from a single cell.
Reporter Plasmid Constructs
The plasmids were constructed using a pGL3 basic luciferase reporter backbone
(Promega, Madison, WI) containing ampicillin resistance and the luciferase gene. The
DNA sequence of the variable heavy chain (VH) (179 bp, AJ851868.3 from 562798 to
562976, NCBI), gamma3 (Iγ3) (176 bp, NG_001019.6 from 1104579 to 1104754, NCBI)
or epsilon (Iε) (291 bp, X56797.1 from 239 to 529, NCBI) promoters was inserted into the
5’ multiple cloning site within the pGL3 luciferase reporter, and the human 3’IGHRR
enhancers hs3, hs1.2, hs4 were inserted into 3’ of the luciferase gene in the pGL3 reporter
plasmid containing one of the above promoters (Fig. 7). The plasmid constructs have the
intervening sequences between hs3 and hs1.2 but lack the intervening sequences between
hs1.2 and hs4 enhancers because this part is about 10 kb that makes it difficult to include
it in plasmid construct.
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Figure 7. Human 3’IGHRR reporter plasmid constructs with VH, Iγ3 or Iε promoters.
Each plasmid contains a luciferase gene regulated by hs3, hs1.2, hs4 enhancers of the
human 3’IGHRR. They include the intervening sequence between hs3 and hs1.2 enhancers
and lack it between hs1.2 and hs4 enhancers.
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The DRE luciferase reporter has six DRE binding sequences inserted into a pGL3
luciferase reporter with a SV40 promoter (Kress et al., 1998). NFκB luciferase reporter
contains three consensus κB DNA binding sequences derived from the Ig κ light chain
conjugated within the conalbumin promoter (Arenzana-Seisdedos et al., 1993). For the AP1 luciferase reporter plasmid, three AP-1 sequences (Vasanwala et al., 2002) were inserted
into a pGL3 luciferase reporter with a SV40 promoter (Fig. 8).

Figure 8. Luciferase reporters evaluating the activity of the transcription factors
AhR, NFκB, and AP-1. 6x DRE plasmid contains six repeats of DRE motifs upstream of
the SV40 promoter. 3x NFκB plasmid contains three repeats of κB sequence conjugated
with Conalbumin (ConA) promoter. 3x AP-1 plasmid has three AP-1 binding motifs
upstream of the SV40 promoter.

39

Transient Transfection
CL-01 cells (1x107) were pelleted by centrifugation at 500 x g for 5 minutes at 4°C.
The pellet was re-constituted with 10 μg of plasmid and fresh complete media to a total
volume of 200 µl then transferred to a 2mm electroporation cuvette. The cells were
electroporated at 150 V, 1500 μF, and 75 ohms. Multiple transfections were performed for
each plasmid and transfected cells were pooled together then diluted in culture tubes to
obtain 1.5 x 105 cell/ml. Cells were cultured without any treatment [naïve (NA)], or treated
with 0.01% DMSO [vehicle control (VH)] or 30 nM TCDD in absent or presence of cellular
stimulation (1 µg/ml R848 or 6.25 ng/ml CD40L with 50 ng/ml IL-4). In AhR antagonist
(AhRA) experiments, transfected cells in culture tubes were treated with 10 µM AhRA and
incubated for 1 hour at 37oC prior to additional treatments. 2 ml of treated cells (1.5 x 105
cell/ml) were aliquoted into a 12-well plate. The plates were incubated at 37oC in 5% CO2
for 24 or 48 hours.
Following the incubation period, the cells were centrifuged for 5 min at 500 x g at
4oC to collect the pellets. Supernatant was removed and cells were lysed with 1x reporter
lysis buffer (Promega). Lysates were immediately frozen at -80oC. To measure the
luciferase enzyme activity, samples were prepared by thawing on ice then centrifugation
at 14,000 x g for 5 minutes at 4oC. In a glass tube, 20 µl of supernatant was mixed with
100 µl of luciferase substrate reagent (Promega, Madison, WI), then luciferase activity,
measured as relative light units (RLU), was determined using a luminometer (Berthold
Detection Systems, Oak Ridge, TN).
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Transfection Efficiency
When evaluating multiple plasmids or different clonal populations of the CL-01
cells (i.e. AhR knockdown clones), the transfection efficiency was determined by
measuring the amount of luciferase gene within the transfected cells by real-time
polymerase chain reaction (RT-PCR) and normalizing the RLU to the transfection
efficiency relative to either a control plasmid or the WT CL-01 cells. Briefly, DNA was
isolated using a genomic DNA miniprep kit (Sigma) at 2-4 hours post-transfection. Real
time polymerase chain reaction (RT-PCR) was performed on the extracted DNA using
luciferase forward and reverse primers (Table 1) as previously described (Fernando et al.,
2012; Sulentic et al., 2004b). RT-PCR results were compared to a standard curve ranging
from 1 to 1x10-6 ng/µl of a standard luciferase reporter to determine the lucifererase
reporter concentration (ng/µl). The amount of transfected plasmid (ng) was calculated
using the following equation: DNA concentration (ng/µl) x the volume of sample added
(µl) x the sample fold dilution. Number of plasmids/cell was measured using the equation:
[ng of plasmid DNA x (plasmid/ng)] / total cells used in DNA isolation. To normalize the
RLU to transfection efficiency relative to a control (i.e. WT CL-01 cells or a control
plasmid), the calculated plasmid/cell of each transfected cell population was divided by the
calculated plasmid/cell of the control to generate a transfection efficiency factor and the
RLUs of each transfected population was multiplied by the efficiency factor to normalize
the luciferase activity to transfection efficiency relative to a control plasmid or the WT CL01 cells.
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Primer

Primer Sequence

Luciferase forward primer

5’-ACTGGGACGAAGACGAACACTT-3’

Luciferase reverse primer

5’-TCAGAGACTTCAGGCGGTCAA-3’

Table 1. Primers for the luciferase gene to measure transfection efficiency. Forward
and reverse primers specific for the luciferase gene. Transfection efficiency is determined
by measuring using RT-PCR the copies of the luciferase gene in transfected cell
populations.

Protein Isolation and Western Blot
Proteins were isolated by centrifuging cells for 5 minutes at 500 x g then adding 50
µl of mild lysis buffer (1% NP40, 150 mM NaCl, 2 mM EDTA, 10 mM NaPO4) with
protease inhibitors (Complete Mini Protease Inhibitor Cocktail; Roche) to the cell pellet.
For cytoplasmic and nuclear proteins, cells were centrifuged for 5 minutes at 500 x g then
proteins were extracted using nuclear and cytoplasmic extraction kit (Thermo). Samples
were frozen and stored at -80oC. For Western blot analysis, lysates were thawed on ice
then centrifuged at 14,000 x g for 5 minutes. The supernatants were collected and protein
concentration was quantified by Bradford protein assay. Equal amounts of protein were
denatured by heating at 95oC for 5 minutes, and separated by 10% polyacrylamide gel at
100 volts for about one hour. Proteins were transferred to a polyvinylidene fluoride
membrane (PVDF) at 300 mAMPs for 2 hours. Membranes were blocked by 1x tris
buffered saline (TBS) with 5% non-fat milk for 1 to 3 hours at room temperature. After
that, membranes were probed with primary antibody [rabbit anti-AhR (Santa Cruz, cat#
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5579) at 1:1000 dilution; mouse anti-β-actin (Cell Signaling, cat# 3700S) at 1:10,000
dilution; rabbit anti-phospho-Akt (Ser473) (Cell Signaling, cat#4060) at 1:1000 dilution;
rabbit anti-Akt (pan) (Cell Signaling, cat#4691) at 1:1000; rabbit anti-phospho-Src family
(Tyr416) (Cell Signaling, cat#2101) at 1:1000; mouse anti-Src (L4A1) (Cell Signaling,
cat#2110) at 1:1000; mouse anti-GAPDH (Gene Tex, cat#627408) at 1:1000 or mouse antip84 (Gene Tex, cat#70220) at 1:1000], and incubated overnight at 4oC. The membranes
were washed three times for 5 minutes in TBS with 0.05% tween 20 (TBS-T) and then
incubated with a secondary antibody conjugated to horseradish peroxidase (HRP); [donkey
anti-rabbit-HRP 1:20,000 (Promega) or goat anti-mouse-HRP 1:20,000 (Thermoscientific)], and incubated on a rotator for one hour at room temperature. Both primary and
secondary antibodies were diluted in 1x TBS/5% non-fat milk/0.05% tween-20. The
probed membranes were washed again four times in TBS-T and then exposed to a Super
Signal West Femto chemiluminescent substrate (Thermoscientific) and analyzed on a
Chemidoc MP Imager (Biorad).
RNA Extraction and polymerase Chain Reaction (PCR)
RNA was extracted from the cells using Tri-Reagent (Sigma) according the
manufacturer’s protocol. The RNA was converted to cDNA using a High Capacity cDNA
Reverse Transcription kit (Applied Biosystems) following the instructions of
manufacturer. PCR was performed on 100 ng of cDNA using the following: 10x buffer,
dNTPs, Taq polymerase (New England Biolabs), forward and reverse primers (Table 2)
and volume was made up to 25 µl with nuclease-free water. PCR products were run on 1%
agarose gel and analyzed on a Chemidoc MP Imager (Biorad).
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Primer

Primer Sequence

Annealing
temperature

β-actin

FP: 5’-GCGGATGTCCACGTCACACTTCA-3’
RP: 5’-CACCATTGGCAATGAGCGGTTC-3’

58oC

AhR

FP: 5’- GCACCGATGGGAAATGATAC -3’
RP: 5’- TTGACTGATCCCATGTAAGTCTG -3’

59oC

Table 2. β-actin and AhR primers for PCR. Forward and reverse primers specific for βactin and AHR gene with the annealing temperature. FP- forward primer, RP- reverse
primer.

Enzyme-Linked Immunosorbent Assay (ELISA)
CL-01 cells (1.25 x105 cells/ml) were cultured for 96 hours and then centrifuged at
500 x g for 5 minutes at 40C. The supernatants were transfered into 1.5 ml tubes and stored
at -80oC for later analysis of secreted Ig. 96-well plates for ELISA were coated at 4oC
overnight with poly-Ig goat anti-human (GAH) (Southern Biotech, Birmingham, AL)
diluted to 1:1500 in 0.1M sodium carbonate bicarbonate buffer. Plates were washed three
times with 1xPBS with 0.05% Tween-20 then four times with dH2O, then blocked with 1x
PBS with 3% bovine serum albumin (BSA) for 1.5 hours at room temperature. Different
standard concentrations to generate a standard curve and cell supernatant samples were
added and incubated in a dry incubator for 1.5 hours at 37oC. Purified IgG (Bethyl
Laboratories, Montgomery, TX) was used for the standard curve for the IgG ELISA. Plates
were washed three times with 1xPBS with 0.05% Tween-20 then four times with dH2O
and then incubated with goat anti-human IgG HRP-conjugated antibody (Bethyl
Laboratories, Montgomery, TX) at 1:10,000 diluted with 1X PBS with 0.05% Tween 20
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and 3% BSA for 1.5 hours in a dry incubator at 37oC. after the incubation period, plates
were washed three times with 1xPBS with 0.05% Tween-20 then four times with dH2O
then Tetramethylbenzidine (TMB) substrate was added to develop the enzyme reaction.
The reaction was stopped by adding 4N H2SO4 and the color changed to yellow.
Absorbance was read with a SpectramaxPlus microplate Spectrophotometer at 450 nM.
The SOFTmax PRO software was used to calculate the sample Ig concentrations using the
standard curve.
CRISPR/Cas9 Gene Editing
The CRISPR plasmid (pCas-Guide-EF1a-GFP) was purchased from Origene (Rockville,
MD). The plasmid was cut using the restriction enzymes BamHI and Esp3I (an
isoschizomer of BsmBI) and the cut plasmid was purified from a 1% agarose gel in
preparation for cloning the targeting sequences. The targeting sequences specific for the
human AHR gene (Fig. 9 and table 3) were inserted into the cut plasmid using T4 ligase
(Promega) and the ligated plasmids were transformed into chemically competent E. coli
(Zymo). Isolated colonies were plucked from an LB agar plate, grown in a 3 ml culture of
LB broth, and the plasmids extracted via miniprep (Zymo). The minipreps were screened
for successful insertion of the targeting sequence by DNA sequencing (Retrogen). When a
successfully cloned plasmid was identified a transfection-quality preparation of the
plasmid was created using an endotoxin-free maxiprep kit (Qiagen). The CRISPR plasmid
was transfected into CL-01 cells and the transfected cells were allowed to incubate for 72
hours at a concentration of 1 x 105 cells/ml and were then sorted for GFP expression by the
Research Flow Cytometry Core at Cincinnati Children’s Hospital. Cells expressing GFP
were seeded into a 96-well plate at 1 cell/well. When the cells outgrew the 96-well plate,
45

they were transferred to a 24-well plate. When sufficient cell numbers were achieved, a
portion of the cells were collected for protein, DNA and RNA analysis.

Figure 9. The human AHR gene with CRISPR targets. The targeting sequence for
CRISPR plasmid 1 (T1) and 2 (T2) are in exon 1, and CRISPR plasmid 3 (T3) is in exon
2 of the AHR gene. Basic helix–loop–helix domain (bHLH); ligand binding domain (LBD);
Per/Arnt/Sim domain (PAS) and transactivation domain (TAD).

Target #

CRISPR Target

Targeting Sequence

T1

AhR exon 1, 24-43F

AGTAGCCGCCGCCGTCGGCT

T2

AhR exon 1, 73-92F

TCACCTACGCCAGTCGCAAG

T3

AhR exon 2, 45-64RC

AAGTCGGTCTCTATGCCGCT

Table 3. CRISPR/Cas9 targeting sequences. These targeting sequences were cloned into
the CRISPR plasmids following the manufacturer’s (Origene) instructions.
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Statistical Analysis
Comparisons between treatment groups were analyzed using a 1-way ANOVA followed
by a Dunnett’s Multiple Comparison test. GraphPad Prism software was used to determine
significant differences between treatment groups (mean ± SEM) and the corresponding
vehicle control as represented by “*”, “**”, “***” at p<0.05, p<0.01 and p<0.001,
respectively. Significant differences between clones and WT clone were denoted by †, ††
and †††, at p<0.05, p<0.01 and p<0.001, respectively. Comparisons between treatment
groups and VH of each time point were analyzed using a two-way ANOVA followed by a
Bonferroni post-tests, significant differences were denoted by “*”, “**”, “***” which
represents significance at p<0.05, p<0.01 and p<0.001, respectively. Significant
differences between AhRA groups and AhRA plus TCDD were denoted by “#”, “##”,
“###”, at p<0.05, p<0.01 and p<0.001, respectively.
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III RESULTS
The role of the AhR on the activation of cytosolic signaling proteins.
Previous studies in a mouse B-cell line stimulated with LPS demonstrated a
concentration-dependent inhibition of IgM secretion (Sulentic et al., 1998). In another
study using human primary B cells, TCDD reduced IgM expression in nine of twelve
human donors while having no effect in two donors and enhancing IgM expression in one
donor (Lu et al., 2010). In a previous study in our lab, using a human B-cell line that can
be induced to secrete antibodies, IgM secretion was fairly unresponsive to treatment with
TCDD or the AhRAs CH223191 or 6,2’,4’,-trimethoxyflavone (TMF) (Panstingel 2017,
unpublished data). In contrast, IgG secretion was inhibited by TCDD and surprisingly
increased by AhRA. Moreover, TCDD inhibited the induction of Cγ1-4 germline/functional
transcripts while the AhRA alone increased all of the Cγ1-4 germline/functional transcripts
(Burra 2015, unpublished data). Our lab has also used shRNA to target and degrade AhR
mRNA and knockdown (KD) the AhR protein levels. IgM secretion was unaffected by
AhR KD, whereas IgG levels were nearly eliminated with AhR KD. Treatment with the
AhRA had little effect on IgG secretion in the AhR KD cells suggesting that the AhRA
effect is AhR dependent (Kashgari 2015, unpublished data). These data suggest a
physiological role of the AhR (independent of ligand) on IgG expression and that the
AhRA may induce a conformational change in the cytosolic AhR that results in an
activation of other signaling proteins. The AhRA prevents translocation of the AhR into
the nucleus and inhibits its activation (Kim et al. 2006) but binding of the AhRA could
influence interaction of the AhR with other cytosolic proteins to lead to the increase in IgG
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secretion. Therefore, the objective of these studies was to determine if AhRA treatment
activated cytosolic signaling pathways known to play a role in B-cell differentiation and Ig
production and previously shown to interact with the AhR.
Previous studies in our lab has shown AhR binding to DRE in the mouse hs1.2 and
hs4 enhancers of the 3’IghRR following TCDD treatment (Sulentic et al., 2000; Salisbury
& Sulentic, 2015). Interestingly, our human B-cell line model (CL-01) is heterozygous for
the AhR and expresses a non-functional transactivation domain in one of its alleles due to
three SNPs (Kashgari 2015, unpublished data) that could decrease the functional activity
of the AhR. In this study, CL-01 cells were transfected with a DRE reporter and treated
with TCDD and/or AhRA (Fig. 10). While TCDD treatment alone had no effect on DRE
activity, AhRA at 10 µM nearly completely inhibited basal DRE activity, which was
partially reversed by 30 nM TCDD reversed the inhibitory effect of AhRA (Fig. 10). These
results suggest a high basal activity of the DRE reporter that is AhR-dependent. The AhRA
prevents translocation of the AhR into the nucleus and inhibits its binding to DRE motifs
while TCDD competes with the AhRA for binding to the AhR in the cytosol and increases
AhR translocation into nucleus. The unexpectedly high basal activity of the DRE suggests
either basal translocation of the AhR perhaps via an unknown endogenous ligand or
increased activity of the SV40 promoter. To determine if either was responsible for the
high basal activity of the DRE reporter, first a luciferase reporter containing only the SV40
promoter (without DRE motifs) was used to compare its basal activity with the DRE
reporter. The result showed that the SV40 reporter plasmid had very low luciferase activity
compared to the DRE reporter activity (Fig. 11), indicating that the increase in DRE
reporter activity was mediated by the transcriptional activity of the DRE binding sites and
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not from high basal activity of the SV40 promoter. This suggest that the basal activity of
the DRE reporter could be from nuclear AhR. Therefore, the cytosolic and nuclear AhR
was evaluated by Western blot analysis. Human CL-01 cells were treated with TCDD and
AhRA. After cultured the cells for 24 hours, the cells were collected and lysed by cytosolic
lysate buffer and transferred the supernatant containing the cytosolic proteins into new
tubes. The nuclear pellets were lysed with nuclear lysate buffer in order to extract nuclear
proteins. Both cytosolic and nuclear extractions were examined for AhR protein (Fig. 12).
The Western blot identified nuclear AhR in naïve cells, which may account for the high
basal activity of the DRE reporter.
Src protein kinase is associated specifically with the cytosolic AhR complex along
with hsp90 and upon ligand binding to the AhR, Src is activated and released from the
complex (Enan & Matsumura, 1996). Since the AhRA competes with TCDD for binding
to the AhR, and then prevents the AhR from translocating to the nucleus (Kim et al. 2006),
we hypothesized that AhRA binding also results in Src disassociation and activation in the
human CL-01 B cells. Human CL-01 B cells were stimulated with R848 and treated with
AhRA for different time points (5 min, 15 min, 30 min, 2 h and 24 h). At each time point,
cells were collected and lysed in order to extract proteins and examine for Src
phosphorylation. Phospho-Src (Y416) antibody has been used to detect Src phosphorylated
at tyrosine 416, which is located in the activation loop and required for optimal activity of
Src (Frame, 2002). Most previous studies have used phospho-Src (Y416) antibody to detect
activated Src kinase in Western blot analysis (Dong et al., 2011), including human B cells
(Ye et al., 2016). Unexpectedly, phospho-Src was not detected at any time point, with or
without cellular stimulation and AhRA treatment (Fig. 13), suggesting that the R848
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stimulation does not induce phosphorylation of Src, which may require other stimulation
such as BCR activation.
The Akt signaling pathway plays a crucial role in multiple cellular processes,
including cell proliferation, angiogenesis, metabolism, differentiation and survival. Basal
expression of phospho-Akt was observed in a Burkitt lymphoma cell line under untreated
conditions (Huang et al., 2012). Many studies have showed that AhR regulates Akt
activation (Wu et al., 2007; Al-Dhfyan et al., 2017). These studies indicate that Akt kinase
is activated during B-cell differentiation and class switching. As the AhRA keeps the AhR
in the cytoplasm and prevents its translocation into the nucleus, we suspected the AhRA
could increase Akt activity. Western blot analysis showed that Akt is basally
phosphorylated in CL-01 cells (Fig. 14A) but after 30 minutes of AhRA and R848 cotreatment, Akt phosphorylation significantly increased and at 2 hours returned to basal
phosphorylation level (Fig. 14B). This indicates that the cytosolic AhR could activate the
Akt pathway after 30 minutes of AhRA treatment, which might lead to increase IgG
production.
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Figure 10. Concentration-dependent decrease of DRE reporter activity by AhRA. A.
The DRE luciferase reporter has six DRE binding sequences inserted into a pGL3
luciferase reporter with a SV40 promoter. B. CL-01 cells were transiently transfected with
the DRE reporter, and were either cultured in the absence of any additional treatment
(naïve, NA) or with the vehicle control (VH, 0.01% DMSO), TCDD (30nM) or AhRA
(0.01, 0.1, 1, 10 µM), then incubated at 37oC for 24 hours. Luciferase enzyme activity is
represented on the y-axis as relative light units (RLU). Comparisons between the treatment
groups were analyzed using a two-way ANOVA followed by a Bonferroni post-tests.
Significant differences between treatment groups and VH were denoted by ** and ***,
which represents significance at p<0.01 and p<0.001, respectively. Significant differences
between AhRA groups and AhRA+30nM TCDD were denoted by ## and ###, which
represents significance at p<0.01 and p<0.001, respectively. Results are representative of
three independent experiments (mean SEM, n=3).
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Figure 11. Low SV40 reporter activity compared to DRE reporter activity. CL-01
wild type (WT) cells were transiently transfected with the DRE reporter or SV40 reporter,
and were either cultured in the absence of any additional treatment (naïve, NA) or with the
vehicle control (VH, 0.01% DMSO) or TCDD (30 nM), then incubated at 37oC for 24
hours. Comparisons between the treatment groups were analyzed using a one-way
ANOVA followed by a Dunnett’s Multiple Comparison post-test. Results are
representative of three independent experiments (mean SEM, n=3).

Figure 12. Nuclear AhR in naïve cells. CL-01 cells were cultured without further
treatment naïve (NA) or treated with vehicle (VH, 0.01% DMSO), 10 µM AhRA (A) or
both AhRA and 30 nM TCDD (A+T). Whole cells (C), cytoplasmic and nuclear proteins
were isolated. 30 μg of proteins were subjected to Western blot analysis. All membranes
were probed with antibodies specific for AhR (122 kDa), p84 (84 kDa, nuclear loading
control) or GAPDH (37 kDa, cytoplasmic loading controls). Results are representative of
three independent experiments.

53

Figure 13. The AhRA has no effect on Src activation. CL-01 cells were cultured without
treatment naïve (NA) or stimulated with 1µg/ml R848 (C), R848 plus vehicle 0.01%
DMSO (VH) or R848 plus 10 µM AhRA (A). Cells were lysed with mild lysis buffer
containing protease and phosphatase inhibitors at different time points (5 min, 15 min, 30
min, 2 h, 24 h). 30 μg of proteins were subjected to Western blot analysis. All membranes
were probed with antibodies specific for phospho-Src (60 kDa), Src (60 kDa) or β-actin
(42 kDa). Src and β-actin served as loading controls. Results are representative of three
independent experiments.
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Figure 14. The AhRA increases Akt activity after 30 minutes. A. CL-01 cells were
cultured without treatment naïve (NA) or stimulated with 1µg/ml R848 (C), R848 plus
vehicle 0.01% DMSO (VH) or R848 plus 10 µM AhRA (A). Cells were lysed with mild
lysis buffer containing protease and phosphatase inhibitors at different time points (5 min,
15 min, 30 min, 2 h, 24 h). 30 μg of proteins were subjected to Western blot analysis. All
membranes were probed with antibodies specific for phospho-Akt (60 kDa) or β-actin (42
kDa), which served as loading controls. B. Densitometric estimation of expression was
graphically represented for phospho-Akt. Fold change normalized to the corresponding VH
in each time point. Results are representative of three independent experiments (mean
SEM, n=3). Comparisons between the treatment groups were analyzed using a two-way
ANOVA followed by a Bonferroni post-tests. Significant differences between treatment
groups and VH were denoted by (*), which represents significance at p<0.05.

55

In B-lymphocytes, the 3’IGHRR enhancers contain numerous transcription factorbinding sites within hs1.2 and hs4 enhancers. The hs1.2 enhancer is polymorphic due to
the potential of having one to four 55 bp invariant sequences. The invariant sequence
contains a DRE, NFκB, SP-1, NF-1 and AP-1 binding site (Pinaud et al., 2011). Because
of the important role of NFκB in B-cell activation and activity of the mouse 3’IghRR, we
measured NFκB transcriptional activity using a luciferase reporter plasmid that has three
consensus NFκB binding motifs. CL-01 cells were transfected with the NFκB reporter
plasmid then stimulated with R848. and treated with 30nM TCDD and 10µM AhRA. As
expected of a TLR ligand, R848 stimulation significantly increased NFκB activity but
TCDD and AhRA had no effect on NFκB activity (Fig. 15). The AhRA and TCDD do not
appear to influence any interaction between the AhR and NFκB pathways.
AP-1 is another transcription factor binding site in the hs1.2 enhancer of the
3’IGHRR (Pinaud et al., 2011). Since it plays an important role in B-cell differentiation,
we utilized a luciferase reporter with three AP-1 binding motifs to measure the
transcriptional activity of AP-1. The CL-01 cells were transfected with the AP-1 plasmid
then stimulated with 1 µg/ml R848 and treated with 30nM TCDD or 10µM AhRA. AP-1
activity was not affected by TCDD or AhRA in either stimulated nor unstimulated cells.
Surprisingly, R848 stimulation decreased AP-1 transcriptional activity (Fig. 16). This
result suggests that AP-1 does not mediate an increase in IgG production by R848
stimulation or AhRA and the AhRA does not disrupt the activation of AP-1 pathway
proteins like fos and jun proteins.
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Figure 15. The AhRA and TCDD had no effect on NFκB activation. A. The NFκB
luciferase reporter plasmid construct which contains three κB motifs conjugated within a
Conalbumin A promoter (ConA). B. CL-01 cells were transiently transfected with the
NFκB plasmid and incubated for 24 hours at 37oC. Transfected cells were stimulated with
R848 (1 μg/ml) in all groups except naïve (NA) and vehicle (VH, 0.01% DMSO). Cells
were stimulated with R848 alone (C) or with the vehicle control (VH, 0.02% DMSO),
TCDD (30nM), or AhRA (10µM). Luciferase enzyme activity is represented on the y-axis
as relative light units (RLU). Results are representative of three independent experiments
(mean SEM, n=3). Comparisons between the treatment groups were analyzed using a oneway ANOVA followed by a Dunnett’s Multiple Comparison post-test. Significant
differences between stimulated VH and VH alone were denoted by
significance at p<0.001.
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Figure 16. The AhRA and TCDD have no effect on AP-1 activity but cellular
stimulation inhibits it. A. The AP-1 luciferase reporter has three AP-1 binding sequences
inserted into a pGL3 luciferase reporter with a SV40 promoter. B. CL-01 cells were
transiently transfected with the AP-1 plasmid and incubated for 24 hours at 37oC.
Transfected cells were incubated in absent of treatments naïve (NA) or treated with vehicle
(VH, 0.01% DMSO), TCDD (30nM) or AhRA (10µM). Cells were stimulated with R848
alone (C) or with the vehicle control (VH, 0.02% DMSO), TCDD (30nM), or AhRA
(10µM). Results are representative of three independent experiments (mean SEM, n=3).
Comparisons between the treatment groups were analyzed using a one-way ANOVA
followed by a Dunnett’s Multiple Comparison post-test. Significant differences between C
group and unstimulated VH group were denoted by (*), which represents significance at
p<0.05.
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Differential effects of TCDD and AhR antagonist on the human 3’IGHRR in CL-01
cells.
B-cell stimulation would be expected to increase the activity of the 3’IGHRR
enhancers since B-cell stimulation is known to increase the transcriptional activity of the
IGH gene, which is at least partially driven by the 3’IGHRR based on mouse studies.
TCDD treatment was expected to result in reduced activity of the plasmids since TCDD is
known to act as an immunosuppressant in both mouse and human B cells. The
transcriptional activity of mouse 3’IghRR in mouse CH12.LX cells was increased with
LPS stimulation, and inhibited when stimulated cells were co-treated with TCDD (Sulentic
et al., 2004a). The human 3’IGHRR activity has been evaluated in human CL-01 cells and
mouse CH12.LX cells in response to B-cell stimulation or TCDD. The CH12.LX cells
transfected with human 3’IGHRR showed more sensitivity to TCDD as well as LPS
stimulation. The human 3’IGHRR activity was induced by LPS and inhibited by TCDD,
which is similar to the effect on the mouse 3’IghRR activity. By contrast, 3’IGHRR activity
in the human CL-01 cell line with either the VH promoter or the intronic promotors Iγ3 or
Iε exhibited variable and statistically insignificant change in response to TCDD or
stimulation (R848 or CD40L plus IL-4) (Alfaheeda 2016, unpublished data). In another
study with CL-01 cells, there was no upregulation of CYP1A1 mRNA expression in
response to TCDD (Burra 2015, unpublished data). Consequently, these results suggested
that the AhR in the CL-01 cells might be not functional. As described above, sequence
analysis found that the AhR is heterozygous in CL-01 cells, likely with a non-functional
transactivation domain in one of its alleles due to the presence of three SNPs (P517S,
R554K, and V570I) in Exon 10 (Kashgari 2015, unpublished data). Exon 10 encodes the
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transactivation domain that regulates expression of other genes (Harper et al. 2002). These
SNPs were demonstrated to impair the ability of CYP1A1 induction by TCDD (Wong et
al., 2001). Therefore, we hypothesized that the lack of sensitivity of the 3’IGHRR to TCDD
is due to not having two AhR alleles with functional transactivation domains. Our lab used
CRISPR/Cas9 gene editing to target the AhR gene with the goal of inducing an insertion
or deletion mutation to prevent AhR gene expression. After screening and characterizing
many clones, a small number of clones appeared to have a monoallelic knockout of the
AhR based on Western analysis and DRE reporter inducibility by TCDD. Further analysis
was conducted on one clone that appeared to have a monoallelic knockout and expressed
an AhR with a functional transactivation domain (AhR TA) (Panstingel 2017, unpublished
data). As demonstrated above in Fig. 10, TCDD treatment did not induce the 6x DRE
reporter in CL-01 wild type cells but in the monoallelic knockout clone, TCDD induced
the DRE reporter (Fig. 17). This suggests that the CL-01 wild type cells may express a
dominant negative AhR due to the heterozygous presence of SNPs in the transactivation
domain of the AhR (Kashgari 2015, unpublished data).
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Figure 17. TCDD induced the DRE reporter in CL-01 cells targeted for AhR gene
editing by CRISP/Cas9. A. CL-01 WT cells were transiently transfected with the DRE
reporter plasmid and cultured for 24 hours. B. CL-01 AhR TA cells were transiently
transfected with the DRE reporter plasmid and cultured for 24 hours. All transfected cells
were either cultured in the absence of any additional treatment (naïve, NA) or treated with
the vehicle control (VH, 0.01% DMSO) or 30 nM TCDD. The graphs on the left represent
luciferase activity as relative light units (RLU) and graphs on the rights represent the fold
change in luciferase activity compared to VH control that was generated from averaging
the means of three independent experiments. Comparisons between the treatment groups
were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple Comparison
post-test. Significant differences between treatment groups and VH were denoted by *,
which represents significance at p<0.05. (mean SEM, n=3).
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To determine if the sensitivity of the 3’IGHRR to TCDD is dependent on the AhR
transactivation domain, 3’IGHRR luciferase reporters were transfected into CL-01 WT
cells and CL-01 AhR TA cells, which appear to express a transactivation functional AhR.
There was little to no effect of CD40L plus IL-4 stimulation or TCDD treatment on
3’IGHRR activity with the VH promoter in both CL-01 WT cells and CL-01 AhR TA cells
(Fig. 18). Additionally, we evaluated the effect of stimulation and TCDD on the 3’IGHRR
when linked with the intronic promoters Iγ3 or Iε. The intronic promoters are involved in
promoting CSR and may interact more with the 3’IGHRR as compared to the VH promoter
(Bottaro 1997, Stavnezer 1996). Moreover, the Iγ3 promoter has a DRE core motif that the
AhR could bind to and mediate a TCDD effect. Additionally, the Iε promoter has IL-4
binding sites that should make this promoter more sensitive to CD40L plus IL4 stimulation
(Delphin, 1995). Interestingly, in both CL-01 WT and AhR TA cells, stimulation and
TCDD had no effect on 3’IGHRR activity when linked to either intronic promoter (Fig. 19
and 20).
As discussed above, our lab found that co-treatment of stimulation (CD40L plus
IL-4) and AhRA increased the secretion of IgG while TCDD inhibited IgG secretion (Burra
2015, unpublished data). Therefore, the effect of the AhRA on each of the 3’IGHRR
reporter was also analyzed. The VH-3’IGHRR reporter showed no consistent effect of
AhRA treatment in both CL-01 WT and CL-01 AhR TA cells (Fig. 18). In addition, both
CL-01 Cells transfected with the Iγ3-3’IGHRR reporter showed an increase in activity with
AhRA (Fig. 19 and 20), which is compatible with previous results that AhRA increased
the secretion of IgG (Burra 2015, unpublished data). In the plasmid driven by Iε-3’IGHRR
there was an increase in activity in both CL-01 WT and AhR TA cells with AhRA.
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Therefore, AhRA have the same effect on 3’IGHRR activity in both CL-01 wild type and
CL-01 AhR TA. These results indicate that the dysfunction of the AhR transactivation
domain in the CL-01 wild type has no effect on the sensitivity of the 3’IGHRR to TCDD
or AhRA since it has the same effects as in CL-01 cells expressing only an AhR with a
functional transactivation domain.
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Figure 18. TCDD and AhRA have no effect on VH-3’IGHRR reporter activity in CL01 WT and AhR TA cells. A. VH-3’IGHRR luciferase plasmid construct. B. CL-01 WT
cells. C. CL-01 AhR TA cells. All cells were transiently transfected with VH-3’IGHRR
plasmid and cultured for 48 hours. Cells were either cultured in the absence of any
treatment (naïve, NA) or treated with CD40L plus IL-4 stimulation alone (C) or cotreatment stimulation with vehicle control (VH, 0.01% DMSO), 30 nM TCDD, 10 µM
AhRA or TCDD plus AhRA (T+A). The graphs on the left represent luciferase activity as
relative light units (RLU) and graphs on the rights represent the fold change in luciferase
activity compared to VH control that was generated from averaging the means of at least
three independent experiments. Comparisons between the treatment groups were analyzed
using a one-way ANOVA followed by a Dunnett’s Multiple Comparison post-test.
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Figure 19. Iγ3-3’IGHRR reporter activity is not effected by TCDD but increased by
AhRA in both CL-01 WT and AhR TA cells. A. Iγ3-3’IGHRR luciferase plasmid
construct. B. CL-01 WT cells. C. CL-01 AhR TA cells. All cells were transiently
transfected with Iγ3-3’IGHRR plasmid and cultured for 48 hours. Cells were either cultured
in the absence of any treatment (naïve, NA) or treated with CD40L plus IL-4 stimulation
alone (C) or co-treatment stimulation with vehicle control (VH, 0.01% DMSO), 30 nM
TCDD, 10 µM AhRA or TCDD plus AhRA (T+A). The graphs on the left represent
luciferase activity as relative light units (RLU) and graphs on the rights represent the fold
change in luciferase activity compared to VH control that was generated from averaging
the means of at least three independent experiments. Comparisons between the treatment
groups were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple
Comparison post-test. Significant differences between treatment groups and VH were
denoted by * and **, which represents significance at p<0.05 and p<0.01, respectively.
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Figure 20. Iε-3’IGHRR reporter activity is not effected by TCDD but increased by
AhRA in both CL-01 WT and AhR TA cells. A. Iε-3’IGHRR luciferase plasmid
construct. B. CL-01 WT cells. C. CL-01 AhR TA cells. All cells were transiently
transfected with Iε-3’IGHRR plasmid and cultured for 48 hours. Cells were either cultured
in the absence of any treatment (naïve, NA) or treated with CD40L plus IL-4 stimulation
alone (C) or co-treatment stimulation with vehicle control (VH, 0.01% DMSO), 30 nM
TCDD, 10 µM AhRA or TCDD plus AhRA (T+A). The graphs on the left represent
luciferase activity as relative light units (RLU) and graphs on the rights represent the fold
change in luciferase activity compared to VH control that was generated from averaging
the means of at least three independent experiments. Comparisons between the treatment
groups were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple
Comparison post-test. Significant differences between treatment groups and VH were
denoted by * and **, which represents significance at p<0.05 and p<0.01, respectively.
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AhR knockout abrogates IgG secretion
In a mouse B-cell line (CH12.LX) stimulated with LPS, TCDD decreased IgM
secretion, whereas it did not affect IgM secretion in an AhR-deficient B-cell line (BCL-1)
suggesting that the AhR plays an important role in inhibition of IgM secretion by TCDD
(Sulentic et al., 1998). Moreover, AhR knockdown by shRNA or inhibition by an AhR
antagonist reversed TCDD-induced inhibition of IgA secretion but did not alter basal or
stimulation-induced IgA secretion in CH12.LX cells (Wourms & Sulentic, 2015). Another
study with AhR-/- mice showed normal immune function and Ig production after treatment
with TCDD (Vorderstrasse et al., 2001). These provide evidence that the AhR mediates
TCDD-induced inhibition of Ig and B-cell differentiation but it is not required for normal
immune function (Wourms & Sulentic, 2015; Vorderstrasse et al., 2001). However, in a
human B-cell line, our lab previously used shRNA to knockdown the AhR and found a loss
of IgG secretion with knockdown of the AhR. In contrast, TCDD inhibited IgG secretion
in wild type cells and the AhR antagonist increased IgG expression (Kashgari 2015,
unpublished data). Therefore, the objective of the current studies was to confirm the shAhR
knockdown results by generating a stable knockout of the AhR in the CL-01 cells using
CRISPR-Cas9 gene editing. The CL-01 cells were transfected with CRISPR vectors
expressing GFP and guide RNA targeting sequences in exon 1 or in exon 2 of the AhR
gene (Table 3). After sorting GFP+ cells and seeding one cell per well, 284 clones were
grown and screened for AhR expression by Western blot (data not shown). Only three
clones (10F10, 7C8, 8F7) demonstrated low expression of the AhR by Western analysis
(Fig. 21), and they targeted exon 2. These three clones were tested by PCR for AhR mRNA
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expression. Two clones (10F10, 8F7) showed decreased AhR mRNA expression while one
clone (7C8) showed very low expression (Fig. 22).
Since IgG levels were nearly eliminated with AhR KD (Kashgari 2015,
unpublished data) as mentioned above, IgG secretion was evaluated by ELISA in the
CRISPR/Cas9 clones. Cells were stimulated with R848 and treated with TCDD then
incubated for 96 hours. As previously seen with AhR knockdown by shRNA IgG secretion
in the CRISPR/Cas9 clones was not induced with stimulation (Fig. 23). These results
suggest a physiological role of the AhR in IgG expression.
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Figure 21. AhR expression in clones transfected with CRISPR-Cas9 targeting the
exon 2 in the AHR gene. CL-01 wild type (WT) and 8 CRISPR-Cas9 clones were lysed
with mild lysis buffer and 40 μg of protein was subjected to Western blot analysis. All
membranes were probed with AhR antibody (122 kDa) and anti-β-actin (42 kDa), which
served as the loading control. Result is representative of three independent experiments.

Figure 22. AhR mRNA expression in CRISPR-Cas9 clones showing decreased AhR
protein levels. RNA was isolated from CL-01 wild type (WT) and the clones 10F10, 7C8
and 8F7. RNA was converted by reverse transcription into cDNA and 100 ng of cDNA
was amplified using AhR and β-actin primers (Table2). Product size for AhR is 549 bp and
β-actin is 224 bp. Results are representative of three independent experiments.
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Figure 23. Low IgG secretion in CRISPR/Cas9 clones compared to WT. WT and
CRISP/Cas9 clones (10F10, 7C8 and 8F7) were cultured without treatment naïve (NA) or
stimulated with 1 µg/ml R848 (C) and treated in addition to R848 with the vehicle control
0.02% DMSO (VH) or 30nM TCDD. Cells were incubated for 96 hours, then supernatant
collected and analyzed for IgG secretion by ELISA. Results are representative of three
independent experiments (mean SEM, n=3). Comparisons between the treatment groups
were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple Comparison
post-test. Significant differences between treatment groups and VH were denoted by *,
which represents significance at p<0.05, respectively.
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Interestingly, the 10F10 and 8F7 clones appeared to change in the expression level
of the AhR over time. Within about 5 months between the initial analysis and the last
analysis and after about 6 new thaws, Western analysis showed an increased expression of
the AhR in 10F10 and 8F7 while the 7C8 clone still had low AhR expression (Fig. 24). In
addition, AhR mRNA expression was increased in the 10F10 and 8F7 clones while the 7C8
clone still had low expression (Fig. 25). The next step was to evaluate the TCDD effects
on DRE reporter in these clones. TCDD induced the DRE reporter in the 10F10 and 8F7
clones while it did not affect the DRE activity in 7C8 clone (Fig. 26). These data suggest
a monoallelic edit in the 10F10 and 8F7 clones disrupting the AhR allele that has a nonfunctional transactivation domain, resulting in decreased AhR expression. Over time, the
functional AhR allele appears to compensate for the decrease in AhR expression and
returns it to normal expression level. The 7C8 clone showed stable AhR knockdown
suggesting that CRISPR/Cas9 edited and disrupted both AhR alleles.
To evaluate the role of the AhR in the effects of the TCDD and AhRA on 3’IGHRR
activity, CRISPR/Cas9 clones were transfected with the Iγ3-3’IGHRR reporter plasmid.
Transfected cells were stimulated with CD40L plus IL4 and treated with TCDD and AhRA.
TCDD had no effect on the CRISPR/Cas9 clones while the AhRA increased Iγ3-3’IGHRR
reporter activity in the high AhR expression clones, 10F10 and 8F7. In contrast, the AhR
knockdown clone 7C8 was not effected by AhRA (Fig. 27). These results are compatible
with previous results that AhRA increased the secretion of IgG (Burra 2015, unpublished
data) and that IgG expression is dependent on the AhR (Fig. 26 and Kashgari 2015,
unpublished data). To determine if the basal activity of the 3’IGHRR reporters is affected
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by loss of the AhR, the RLUs were normalized to transfection efficiency. The clones
(10F10 and 8F7) with high AhR expression demonstrated significantly increased basal
activity of both the VH-3’IGHRR and Iγ3-3’IGHRR reporter plasmids compared to the WT
while the 7C8 clone had similar basal activity as the WT cells (Fig. 28).

Figure 24. Increased AhR expression in the 10F10 and 8F7 clones. CL-01 wild type
(WT) and CRISPR/Cas9 clones were lysed with mild lysis buffer and 40 μg of protein was
subjected to Western blot analysis. All membranes were probed with antibodies specific
for AhR (122 kDa) and anti-β-actin (42 kDa), which served as the loading control. Results
are representative of three independent experiments

Figure 25. AhR mRNA expression was increased in 10F10 and 8F7 clones. RNA was
isolated from CL-01 wild type (WT) and the clones 10F10, 7C8 and 8F7. RNA was
converted by reverse transcription into cDNA and 100 ng of cDNA was amplified using
AhR and β-actin primers (Table2). Product size for AhR is 549 bp and β-actin is 224 bp.
Results are representative of three independent experiments
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Figure 26. TCDD increased the DRE reporter activity in 10F10 and 8F7 clones but
not in the 7C8 clone. (A) 10F10 clone. (B) 7C8 clone. (C) 8F7 clone. Cells were
transiently transfected with DRE plasmid then cells were either cultured in the absence of
any additional treatment (naïve, NA) or with 0.01% DMSO vehicle control (VH) and 30nM
of TCDD, and then incubated at 37oC for 24 hours. The graphs on the left represent
luciferase activity as relative light units (RLU) normalized to transfection efficiency and
graphs on the rights represent the fold change in luciferase activity compared to VH control
that was generated from averaging the means of at least three independent experiments.
Comparisons between the treatment groups were analyzed using a one-way ANOVA
followed by a Dunnett’s Multiple Comparison post-test. Significant differences between
treatment groups and VH were denoted by ** and ***, which represents significance at
p<0.01 and p<0.001, respectively. (mean SEM, n=3)
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Figure 27. Iγ3-3’IGHRR reporter activity in the AhR knockdown clone 7C8 was not
effected by AhRA. CL-01 WT and CRISPR/Cas9 clones were transiently transfected with
Iγ3-3’IGHRR plasmid and cultured for 48 hours. Cells were either cultured in the absence
of any treatment (naïve, NA) or treated with CD40L plus IL-4 stimulation alone (C) or cotreatment stimulation with vehicle control (VH, 0.01% DMSO), 30 nM TCDD, 10 µM
AhRA or TCDD plus AhRA (T+A). Results are representative of three independent
experiments (mean SEM, n=3). Comparisons between the treatment groups were analyzed
using a one-way ANOVA followed by a Dunnett’s Multiple Comparison post-test.
Significant differences between treatment groups and VH were denoted by * and **, which
represents significance at p<0.05 and p<0.01, respectively.
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Figure 28. The 3’IGHRR basal reporter activities are high in 10F10 and 8F7 clones
but not in 7C8 clone. CL-01 WT and CRISPR/Cas9 (10F10, 7C8 and 8F7) clones were
transiently transfected with Iγ3-3’IGHRR or VH-3’IGHRR plasmid and cultured for 48
hours. Results are representative of three independent experiments (mean SEM, n=3).
Numbers above bars represented the fold-change to the WT clone. Comparisons between
clones were analyzed using a one-way ANOVA followed by a Dunnett’s Multiple
Comparison post-test. Significant differences between clones and WT clone were denoted
by †† and †††, which represents significance at p<0.01 and p<0.001, respectively.
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IV DISCUSSION
The TCDD and AhR mechanisms in inhibition of Ig expression in humans are not
clear yet. In a human B cell line, IgG secretion is inhibited in response to TCDD but
increased about two-fold when the B cells are treated with an AhRA [CH223191 or
6,2’,4’,-trimethoxyflavone (TMF)] (Burra 2015; Panstingel 2017, unpublished data). In
addition, AhR knockdown by shRNA eliminated IgG secretion (Kashgari 2015,
unpublished data). Other studies have shown that AhR can bind to other transcription
factors like SP1, NF-κB and AP-1 (Suh et al., 2002; Tian et al., 1999; Kobayashi et al.,
1996). These data suggest a physiological role of the AhR on IgG expression and that the
AhRA may induce non-genomic effects mediated by the cytosolic AhR that result in
activation of other signaling proteins.
In this study, we determined the activity of the AhR using the DRE reporter. The
DRE reporter plasmid showed highly basal activity and AhRA nearly completely inhibited
this activity, while TCDD reversed the inhibitory effect of AhRA. This suggest a high basal
activity of the DRE reporter that is AhR-dependent. The basal activity of the DRE reporter
is mediated by the transcriptional activity of the DRE binding sites and not from high basal
activity of the SV40 promoter. In addition, Western analysis showed the presence of
nuclear AhR in naive cells that could be responsible for the increased basal activity of the
DRE reporter. A portion of the AhR could be localized in the nucleus independent of ligand
activation or an endogenous ligand may promote a low level of basal AhR activation.
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Additionally, TCDD treatment alone had no effect on DRE reporter activity in the
human CL-01 cells that is very different from mouse B cells in which TCDD enhanced the
AhR binding to DRE sites (Wourms & Sulentic, 2015). In CL-01 human B cells, it was
found that the AhR is heterozygous, likely with a non-functional transactivation domain in
one of its alleles due to the identification of three SNPs (P517S, R554K, and V570I) present
in Exon 10 (Fig. 29) (Kashgari 2015, unpublished data). Exon 10 is a region encoding the
transactivation domain that regulates expression of genes sensitive to the AhR (Harper et
al. 2002). Moreover, These SNPs were demonstrated to impair the ability of CYP1A1
induction by TCDD (Wong et al., 2001). Therefore, the low AhR activity could be due to
a nonfunctional transactivation domain in one of the AhR alleles (Kashgari 2015,
unpublished data). Notably, these exon 10 SNPs do not affect the ligand binding affinity
to the AhR (Harper et al., 2002). And should not affect the potential non-genomic function
of the AhR. Non-genomic functions could be mediated by protein-protein interactions
between the AhR and regulatory proteins such as Src protein kinase and NFκB (Enan and
Matsumura, 1996; Tian et al., 1999). Moreover, the AhR signaling pathway has been
shown to modulate tyrosine kinases associated with the epidermal growth factor receptor
(EGFR) and Akt/PKB (Marlowe & Puga, 2005). Therefore, the biological effects of the
AhR could occur via at least two general mechanisms: direct influence on gene
transcription by binding to DRE motifs and/or modulation of signaling pathways by
protein–protein interaction (Suh et al., 2002).
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Figure 29. Chromatograph showing the three SNPs location in the transactivation
domain of the CL-01 AhR exon 10. The heterozygous SNPs are shown in three positions
with two overlap peaks. Each peak represents a nucleotide with a coded color: green for
Adenine; red for Thymine; black for Guanine and blue for Cytosine (Kashgari 2015,
unpublished data).
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Although the Src protein kinase is associated with the AhR complex in the cytosol
(Enan & Matsumura, 1996), phospho-Src was not in the CL-01 cells with or without
stimulation. However, Src kinases are initially activated after BCR ligation by antigen.
Therefore, signaling through the BCR could be the only pathway to activate Src; whereas,
in these studies R848 stimulation was used, which activates the TLRs 7 and 8. Src
activation may need a BCR ligand to increase B-cell activation and Ig production.
Alternatively, the Src protein associated with the cytosolic AhR complex may only be
released and activated by TCDD binding (Enan & Matsumura, 1996). In other words,
binding of the AhRA may not induce the proper conformational change to release Src.
Moreover, Western blot analysis may not be the most sensitive technique to detect
phospho-Src. In a previous Src study, they used fluorescence resonance energy transfer
(FRET) to visualize and quantify phosph-Src (Tyr416) (Dong et al., 2011).
The Akt protein kinase was also activated by the AhR signaling pathway in several
human cells (Wu et al., 2007; Al-Dhfyan et al., 2017). The results showed that Akt is
basally phosphorylated in CL-01 cells but after 30 minutes of AhRA treatment, Akt
phosphorylation significantly increased and at 2 hours returned to basal phosphorylation
level. In another study using the mouse CH12.LX cell line, the most abundance of p-Akt
was observed within the first 60 minutes after treating R848-stimulated cells with 0.3 nM
TCDD but 30 nM TCDD significantly suppressed R848-activated phosphorylation of Akt
protein, which is compatible with the suppression of Ig production by TCDD (North et al.,
2010). Additionally, Loss of the AhR lead to impaired activation of Akt and enhanced
sensitivity to apoptosis in a hepatoma cell line (LA1) (Wu et al., 2007). Another study
showed that the AhR signaling pathway controls proliferation and development of breast
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cancer cells through activation of Akt pathways (Al-Dhfyan et al., 2017). These studies
indicate that the cytosolic AhR can modulate the Akt pathway. Chemical antagonism of
the AhR in the CL-01 cells appears to induce Akt phosphorylation, which may contribute
to the increase in IgG secretion. Upon phosphorylation of Akt, the Akt signaling pathway
mediates multiple downstream events. Phosphorylated Akt activates the mTOR complex,
causing increased mRNA translation, protein synthesis and cellular proliferation (Agata et
al., 2010). Phosphorylated Akt enters the nucleus to inactivate forkhead box O (FOXO)
protein, which blocks cell cycle progression and promotes stress resistance, which help in
B-cell proliferation (Limon & Fruman, 2012). Moreover, Akt phosphorylation induces
activation of IKKα leading to dissociate NFκB from IκB and increase the NFκB
transcription activity (Liou et al., 1994).
The NFκB has an important role in B-cell activation, activity of the mouse 3’IghRR,
and the AhR physically interacts with NFκB (Tian et al., 1999). In human, the invariant
sequence in the hs1.2 enhancer of the 3’IHGRR contains DRE, NFκB, SP-1, NF-1 and AP1 binding sites (Pinaud et al., 2011). Two separate pathways can activate NFκB; the
“canonical” pathway is triggered by TLR, TNFα and IL-1, and the “alternative” pathway
is activated by CD40L, BAFF and lymphotoxin (Lawrence, 2009). The AhRA could
influence interaction of AhR with any protein in these two pathways that lead to increase
Ig expression. Previous studies in our lab has shown that stimulation with R848, a synthetic
molecule that activates B cells via the TLR7/8, or with CD40L plus IL4 increased IgG
production (Burra 2015, unpublished data). Both methods of stimulation activate either
canonical or alternative NFκB activation pathways (Hanten et al., 2008; Lawrence, 2009),
which suggests that activation of NFκB transcription factors could influence IgG
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production. Our results showed that the R848 stimulation significantly increased the NFκB
plasmid activity but TCDD and AhRA have no effect on NFκB activity. As mentioned,
Akt signaling pathway activates NFκB and this activity should be increased with cells
treated with AhRA because AhRA increase the Akt activity. But the result showed that
NFκB reporter activity was not affected by AhRA. The Akt activates other signaling
pathway like mTOR or FOXO but not NFκB pathway, or Akt may increase the translation
of NFκB but not transcription activity. In addition, the NFκB reporter may not reflect the
complexity of protein-protein interactions and transcriptional regulation that may vary
from gene to gene.
The AP-1 is another transcription factor binding site in the hs1.2 enhancer of the
3’IGHRR (Pinaud et al., 2011). The results suggests that AP-1 has no role in increased IgG
production by AhRA and therefore, the AhRA may not influence an AhR interaction with
AP-1 pathway proteins like c-Fos or c-Jun. Furthermore, R848 stimulation lowered AP-1
suggesting that activation of the TLR7/8 signaling pathway inhibits AP-1 transcriptional
activity. Another possibility is that the CL-01 cells were isolated from a Burkett’s
lymphoma patient. In Birkett’s lymphoma, the B cell lymphoma-6 (BCL-6) gene is
involved in chromosomal translocation that could lead to sustained expression of BCL-6.
The BCL-6 encodes a transcriptional repressor protein that is expressed in B cells in the
germinal center reaction and is down-regulated upon B cell differentiation into plasma cells
(Vasanwala et al.,2002). TLR stimulation of CL-01 cells may activate the BCL-6 that binds
to c-Jun and disrupts dimerization of c-Jun leading to repression of AP-1 activity and
inhibit B cell differentiation (Vasanwala et al.,2002). Previous studies in our lab showed
that both R848 and CD40L plus IL-4 stimulation inhibited the basal activity of the hs1.2
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and hs3-1.2 enhancers, which has the intervening sequences between hs3 and hs1.2,
reporters activity (Freiwan, 2014; Alfaheeda, 2016 unpublished data) suggesting that AP1 may have a positive regulator role in the transcriptional activity of the 3’IGHRR
enhancers in human CL-01 cells stimulated with either R848 or CD40L plus IL-4.
The human and mouse AhR gene have single nucleotide polymorphisms (SNPs) in
different locations and they only share about 58% amino acid sequence in the C-terminal
of the gene that includes the transactivation domain (Flaveny et al. 2008). As mentioned,
CL-01 human B cells have a heterozygous AhR, likely with a non-functional
transactivation domain in one of its alleles due to the identification of three SNPs (Fig. 29)
(Kashgari 2015, unpublished data). These SNPs could be the reason why the human
3’IGHRR is more sensitive to TCDD in a mouse B-cell line that expresses a highly
functional AhR signaling pathway compared to the human (Alfaheeda 2016, unpublished
data). Using an AhR with a functional transactivation domain (AhR TA) (Panstingel 2017,
unpublished data), TCDD induced the DRE reporter activity unlike the CL-01 WT cells
suggesting that these CL-01 WT cells may express a dominant negative AhR. The
dysfunction of the AhR transactivation domain in the CL-01 wild type had no effect on the
sensitivity of the 3’IGHRR to TCDD or AhRA since it has the same effects as in CL-01
cells expressing only an AhR with a functional transactivation domain. Moreover,
Increases in the Iγ3-3’IGHRR reporter activity is compatible with previous results that
AhRA increased the secretion of IgG (Burra 2015, unpublished data) supporting that the
cytosolic AhR induces a non-genomic effect perhaps by interacting with signaling proteins
leading to an increase in IgG secretion and Iγ3-3’IGHRR activity. In addition, TCDD has
no effect on the 3’IGHRR reporter activity may results of the TCDD induces multiple
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interaction of the AhR with different proteins. TCDD induces the crosstalk between AhR
and many signaling pathways like Src, Akt/PKB, NFκB and Wnt/β-catenin (Suh et al.,
2002; Wu et al., 2007; Enan and Matsumura, 1996; Tian et al., 1999) therefore, the nongenomic interaction of the AhR with other proteins may consume the AhR proteins and
decrease nuclear translocation of the AhR.
Previous studies on mouse B cells showed that the AhR mediates TCDD-induced
inhibition of Ig and B-cell differentiation (Wourms & Sulentic, 2015; Vorderstrasse et al.,
2001). Moreover, AhR knockdown by shRNA or inhibition by an AhR antagonist reversed
TCDD-induced inhibition of IgA secretion but did not alter basal or stimulation-induced
IgA secretion in CH12.LX cells (Wourms & Sulentic, 2015). Another study with AhR-/mice showed normal immune function and Ig production after treatment with TCDD
(Vorderstrasse et al., 2001). These provide evidence that the AhR mediates TCDD-induced
inhibition of Ig and B-cell differentiation but it is not required for normal immune function
(Wourms & Sulentic, 2015; Vorderstrasse et al., 2001). However, in a human B-cell line,
IgG secretion was inhibited by TCDD and surprisingly increased by AhRA. Moreover,
TCDD inhibited the induction of Cγ1-4 germline/functional transcripts while the AhRA
alone increased all of the Cγ1-4 germline/functional transcripts (Burra 2015, unpublished
data).Our lab has also used shRNA to target and degrade AhR mRNA and knockdown the
AhR protein levels. IgM secretion was unaffected by AhR knockdown, whereas IgG levels
were nearly eliminated with AhR knockdown (Kashgari 2015, unpublished data). These
observations match with our results for AhR knockdown (KD) using the CRISPR/Cas9
gene editing. The AhR KD clone inhibited IgG secretion as previously seen with AhR
knockdown by shRNA suggesting a physiological role of the AhR in IgG expression. In
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addition, the result suggests that the non-functional transactivation domain of the AhR has
no effect on IgG production. CRISPR/Cas9 clones that have edited the nonfunctional AhR
transactivation domain (TA) allele appeared to change in the expression level of the AhR
over time. Suggesting the functional AhR TA allele, which not edited by CRISPR/Cas9,
appears to compensate for the decrease in AhR expression and returns it to normal
expression level. While the knockdown clone showed stable AhR knockdown suggesting,
that CRISPR/Cas9 edited and disrupted both AhR alleles.
Although TCDD had no effect on Iγ3-3’IGHRR reporter activity in CL-01 WT,
AhR TA and AhR KD clones, the AhRA increased Iγ3-3’IGHRR activity in CL-01 WT
and AhR TA clones while it has no effect in the AhR KD clone. Indicating that TCDD has
no effect on 3’IGHRR regardless of AhR expression or function while the AhRA could
influence the interaction of the cytosolic AhR with signaling proteins leading to an increase
in Iγ3-3’IGHRR activity that could increase IgG secretion supporting an AhR non-genomic
effect and a physiological role of the AhR in the expression of IgG. Furthermore, the basal
activity of the 3’IGHRR reporters in the AhR knockdown clone was lower than in the AhRexpressing cells indicates the AhR mediated the basal activity of the 3’IGHRR reporters.
A limitation of using reporter plasmids is that they may not actually reflect enhancer
activity in the context of chromatin. Additionally, the 3’IGHRR reporter constructs lack
the intervening sequence between hs1.2 and hs4 enhancers because it is difficult to include
in the reporter because of size. The current 3’IGHRR reporter contains about 10 kb while
the intervening sequence between the hs1.2 and hs4 enhancers is about 10 kb. This
intervening sequence may play a critical role in 3’IGHRR function since it contains
transcription factor binding sites and has a unique repetitive nucleotide sequences that may
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contribute to the secondary structures of the 3’IGHRR and may affect its function (Giambra
et al., 2005). In addition, the 3’IGHRR reporter plasmids behave differently depending on
if they are transfected into mouse or human B-cell lines. Previous work has shown that a
plasmid containing just the human hs1.2 enhancer will show a decrease in activity in
response to B-cell stimulation when transfected into human B cells, whereas in mouse B
cells stimulation will increase its activity (Fernando et al., 2012; Freiwan 2014,
unpublished data). Moreover, the 3’IGHRR reporters have only one of the two 3’IGHRRs
and perhaps both work in concert for expressing some of the CH isotypes. We also had
difficulty sequencing exon 1 and exon 2 of the AhR to determine the edits induced by
CRISPR/Cas9. We have tried to amplify and sequence the exon 1 and exon 2 in order to
confirm the CRISPR/Cas9 edit. We suspect that these areas are polymorphic, preventing
primers based on a reference AhR gene from binding within the CL-01 AhR gene. Ongoing
studies in our lab are tring to address this peoblem by using a method called rapid
amplification of 5′ complementary DNA ends (5′ RACE) in order to sequence the exons 1
and 2 of the AhR gene. This method is used to extend partial cDNA clones by amplifying
the 5′ sequences of the corresponding mRNA.
In future studies, we should expand the signaling analysis to cover most of the Bcell signaling pathways such as Ca2+, Syk pathways or transcription factors like SP1 and
NFAT that could interact with AhR in order to understand the AhR role in IgG production.
Studies should also focus on analysis of all Akt signaling pathways such as mTOR and
FOXO pathways to define if AhRA has an effect on one of these pathways to mediate the
increase IgG secretion. Measuring the Akt in the AhR knockdown clone could confirm the
interaction of AhR with Akt protein. In addition, using gene editing like CRISPR/Cas9
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technique to mutate or delete specific 3’IGHRR enhancers in order to determine the role
of this enhancer in TCDD and AhRA effects. Moreover, a cell line with two
transcriptionally function AhR alleles must be used to test the effect of TCDD on human
3’IGHRR enhancers. Additionally, using different human B cell line with specific
characteristics representing normal human B cells may provide better understanding for
the human 3’IGHRR and the effect of TCDD on it. An ongoing work in our lab on another
B cell line (U266), which is a human B cell line isolated from myeloma may add more
knowledge about B cells sensitivity to TCDD in different stages of B cell development.
In conclusion, our results suggest that the AhRA nearly completely inhibits AhR
translocation into the nucleus and TCDD reverses this inhibition. B cells have nuclear AhR
that could be localized in the nucleus independent of ligand activation or an endogenous
ligand may promote a low level of basal AhR activation. The AhR has non-genomic effects
by activating cytosolic signaling protein like Akt and increasing the Iγ3-3’IGHRR reporter
activity in response to AhRA that could lead to an increase in IgG secretion. Interestingly,
the dysfunction of the AhR transactivation domain in the CL-01 wild type has no effect on
the sensitivity of the 3’IGHRR to TCDD or AhRA suggesting that the AhRA is mediating
non-genomic effects through the AhR. AhR knockdown by gene editing markedly
inhibited IgG secretion, both basal and induced, and AhRA has no effect on Iγ3-3’IGHRR
activity supporting an AhR non-genomic effect and a physiological role of the AhR in the
expression of IgG. Significantly, understanding how the AhR-ligands modulate Ig
expression and CSR and its relation to the 3’IGHRR will provide insight into how
chemically-induced immunotoxic effects are mediated. The human 3’IGHRR has a
polymorphism in the hs1.2 enhancer that has been associated with Burkitt’s lymphoma and
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a number of autoimmune disorders such as celiac disease, psoriatic arthritis, IgA
nephropathy, rheumatoid arthritis, systemic sclerosis, and plaque psoriasis. Consequently,
determining the role of the 3’IGHRR and its potential difference in sensitivity to the AhR
could provide new insight into potential environmental triggers of immune disorders and
provide new targets for drug development.
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